CA2770851C - Blockade of t lymphocyte down-regulation associated with ctla-4 signaling - Google Patents

Blockade of t lymphocyte down-regulation associated with ctla-4 signaling Download PDF

Info

Publication number: CA2770851C
Authority: CA; Canada
Prior art keywords: ctla; cells; antibody; cell; tumor
Prior art date: 1995-12-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA2770851A

Other languages

English (en)

French (fr)

Other versions

CA2770851A1 (en

Inventor

James Patrick Allison

Dana R. Leach

Matthew F. Krummel

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of California San Diego UCSD

Original Assignee

University of California San Diego UCSD

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-12-04

Filing date

1996-12-04

Publication date

2013-09-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27074292&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2770851(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-12-04 Priority claimed from US08/566,853 external-priority patent/US5855887A/en

1996-12-04 Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD

1997-06-12 Publication of CA2770851A1 publication Critical patent/CA2770851A1/en

2013-09-24 Application granted granted Critical

2013-09-24 Publication of CA2770851C publication Critical patent/CA2770851C/en

2016-12-04 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

230000011664 signaling Effects 0.000 title claims abstract description 23
210000001744 T-lymphocyte Anatomy 0.000 title description 86
230000003828 downregulation Effects 0.000 title description 2
229940045513 CTLA4 antagonist Drugs 0.000 claims abstract description 252
102000008203 CTLA-4 Antigen Human genes 0.000 claims abstract description 169
108010021064 CTLA-4 Antigen Proteins 0.000 claims abstract description 169
206010028980 Neoplasm Diseases 0.000 claims abstract description 91
102000036639 antigens Human genes 0.000 claims abstract description 61
108091007433 antigens Proteins 0.000 claims abstract description 61
239000000427 antigen Substances 0.000 claims abstract description 60
238000011282 treatment Methods 0.000 claims abstract description 45
210000004027 cell Anatomy 0.000 claims description 222
210000004881 tumor cell Anatomy 0.000 claims description 52
230000027455 binding Effects 0.000 claims description 35
239000012634 fragment Substances 0.000 claims description 26
102000004127 Cytokines Human genes 0.000 claims description 25
108090000695 Cytokines Proteins 0.000 claims description 24
238000002360 preparation method Methods 0.000 claims description 16
201000009030 Carcinoma Diseases 0.000 claims description 13
201000001441 melanoma Diseases 0.000 claims description 11
239000008194 pharmaceutical composition Substances 0.000 claims description 11
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 8
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 8
239000003814 drug Substances 0.000 claims description 6
230000004044 response Effects 0.000 abstract description 43
230000001965 increasing effect Effects 0.000 abstract description 21
230000003053 immunization Effects 0.000 abstract description 20
238000002649 immunization Methods 0.000 abstract description 19
230000005867 T cell response Effects 0.000 abstract description 15
230000005764 inhibitory process Effects 0.000 abstract description 12
230000006044 T cell activation Effects 0.000 abstract description 11
239000002671 adjuvant Substances 0.000 abstract description 9
230000001684 chronic effect Effects 0.000 abstract description 7
230000009385 viral infection Effects 0.000 abstract description 4
208000036142 Viral infection Diseases 0.000 abstract description 3
239000011230 binding agent Substances 0.000 abstract description 2
241000699670 Mus sp. Species 0.000 description 62
108090000623 proteins and genes Proteins 0.000 description 57
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 56
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 56
235000018102 proteins Nutrition 0.000 description 42
102000004169 proteins and genes Human genes 0.000 description 42
241000282414 Homo sapiens Species 0.000 description 40
230000000694 effects Effects 0.000 description 39
239000002981 blocking agent Substances 0.000 description 37
239000007924 injection Substances 0.000 description 35
238000002347 injection Methods 0.000 description 35
241001465754 Metazoa Species 0.000 description 34
101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 32
230000035755 proliferation Effects 0.000 description 32
102000043321 human CTLA4 Human genes 0.000 description 31
230000028993 immune response Effects 0.000 description 26
238000000034 method Methods 0.000 description 25
241000699800 Cricetinae Species 0.000 description 24
239000003795 chemical substances by application Substances 0.000 description 24
102000037865 fusion proteins Human genes 0.000 description 24
108020001507 fusion proteins Proteins 0.000 description 24
210000002966 serum Anatomy 0.000 description 24
210000004408 hybridoma Anatomy 0.000 description 20
238000001727 in vivo Methods 0.000 description 20
239000012275 CTLA-4 inhibitor Substances 0.000 description 18
239000000243 solution Substances 0.000 description 18
108091003079 Bovine Serum Albumin Proteins 0.000 description 17
241000699666 Mus <mouse, genus> Species 0.000 description 17
230000004913 activation Effects 0.000 description 17
239000012894 fetal calf serum Substances 0.000 description 17
230000002163 immunogen Effects 0.000 description 17
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 16
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 16
108010002350 Interleukin-2 Proteins 0.000 description 16
102000000588 Interleukin-2 Human genes 0.000 description 16
238000003556 assay Methods 0.000 description 16
239000013604 expression vector Substances 0.000 description 16
238000002474 experimental method Methods 0.000 description 15
239000000203 mixture Substances 0.000 description 15
238000002965 ELISA Methods 0.000 description 14
230000001404 mediated effect Effects 0.000 description 14
102100025137 Early activation antigen CD69 Human genes 0.000 description 13
101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 13
239000002269 analeptic agent Substances 0.000 description 13
230000003993 interaction Effects 0.000 description 13
210000004698 lymphocyte Anatomy 0.000 description 13
230000004927 fusion Effects 0.000 description 12
239000002299 complementary DNA Substances 0.000 description 11
230000012010 growth Effects 0.000 description 11
238000000338 in vitro Methods 0.000 description 11
210000001165 lymph node Anatomy 0.000 description 11
108090000765 processed proteins & peptides Proteins 0.000 description 11
101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 10
101000859077 Mus musculus Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 10
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 10
230000000903 blocking effect Effects 0.000 description 10
201000011510 cancer Diseases 0.000 description 10
230000004073 interleukin-2 production Effects 0.000 description 10
239000002609 medium Substances 0.000 description 10
230000000638 stimulation Effects 0.000 description 10
230000004614 tumor growth Effects 0.000 description 10
239000002246 antineoplastic agent Substances 0.000 description 9
238000004132 cross linking Methods 0.000 description 9
238000010790 dilution Methods 0.000 description 9
239000012895 dilution Substances 0.000 description 9
230000002401 inhibitory effect Effects 0.000 description 9
239000006228 supernatant Substances 0.000 description 9
238000002560 therapeutic procedure Methods 0.000 description 9
210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 9
101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 8
101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 8
102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 8
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 8
241001529936 Murinae Species 0.000 description 8
108010076504 Protein Sorting Signals Proteins 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
239000000872 buffer Substances 0.000 description 8
238000004113 cell culture Methods 0.000 description 8
230000030833 cell death Effects 0.000 description 8
239000006285 cell suspension Substances 0.000 description 8
230000004940 costimulation Effects 0.000 description 8
229940127089 cytotoxic agent Drugs 0.000 description 8
230000006698 induction Effects 0.000 description 8
238000007912 intraperitoneal administration Methods 0.000 description 8
210000000952 spleen Anatomy 0.000 description 8
239000000725 suspension Substances 0.000 description 8
229940104230 thymidine Drugs 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
238000011725 BALB/c mouse Methods 0.000 description 7
108020004414 DNA Proteins 0.000 description 7
241000700159 Rattus Species 0.000 description 7
241000191967 Staphylococcus aureus Species 0.000 description 7
150000001413 amino acids Chemical group 0.000 description 7
238000010348 incorporation Methods 0.000 description 7
208000015181 infectious disease Diseases 0.000 description 7
238000012933 kinetic analysis Methods 0.000 description 7
230000007246 mechanism Effects 0.000 description 7
108020004999 messenger RNA Proteins 0.000 description 7
239000004005 microsphere Substances 0.000 description 7
108020003175 receptors Proteins 0.000 description 7
102000005962 receptors Human genes 0.000 description 7
210000001519 tissue Anatomy 0.000 description 7
239000013598 vector Substances 0.000 description 7
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 6
229930182566 Gentamicin Natural products 0.000 description 6
108091028043 Nucleic acid sequence Proteins 0.000 description 6
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
230000000735 allogeneic effect Effects 0.000 description 6
235000001014 amino acid Nutrition 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
239000012228 culture supernatant Substances 0.000 description 6
230000003247 decreasing effect Effects 0.000 description 6
238000001514 detection method Methods 0.000 description 6
238000009472 formulation Methods 0.000 description 6
230000001717 pathogenic effect Effects 0.000 description 6
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 6
210000004988 splenocyte Anatomy 0.000 description 6
238000007920 subcutaneous administration Methods 0.000 description 6
241000894006 Bacteria Species 0.000 description 5
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 5
206010009944 Colon cancer Diseases 0.000 description 5
201000008808 Fibrosarcoma Diseases 0.000 description 5
108010010803 Gelatin Proteins 0.000 description 5
108060003951 Immunoglobulin Proteins 0.000 description 5
239000012980 RPMI-1640 medium Substances 0.000 description 5
241000700605 Viruses Species 0.000 description 5
238000002835 absorbance Methods 0.000 description 5
238000010171 animal model Methods 0.000 description 5
230000001580 bacterial effect Effects 0.000 description 5
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 5
238000013357 binding ELISA Methods 0.000 description 5
230000006369 cell cycle progression Effects 0.000 description 5
238000007796 conventional method Methods 0.000 description 5
238000000684 flow cytometry Methods 0.000 description 5
230000006870 function Effects 0.000 description 5
239000008273 gelatin Substances 0.000 description 5
229920000159 gelatin Polymers 0.000 description 5
235000019322 gelatine Nutrition 0.000 description 5
235000011852 gelatine desserts Nutrition 0.000 description 5
102000018358 immunoglobulin Human genes 0.000 description 5
238000002955 isolation Methods 0.000 description 5
239000003446 ligand Substances 0.000 description 5
239000013642 negative control Substances 0.000 description 5
244000052769 pathogen Species 0.000 description 5
229920001223 polyethylene glycol Polymers 0.000 description 5
230000002516 postimmunization Effects 0.000 description 5
230000009257 reactivity Effects 0.000 description 5
238000011084 recovery Methods 0.000 description 5
230000003248 secreting effect Effects 0.000 description 5
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Natural products CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 5
238000001890 transfection Methods 0.000 description 5
108010045634 B7 Antigens Proteins 0.000 description 4
102000005738 B7 Antigens Human genes 0.000 description 4
206010011968 Decreased immune responsiveness Diseases 0.000 description 4
229930182816 L-glutamine Natural products 0.000 description 4
102000015636 Oligopeptides Human genes 0.000 description 4
108010038807 Oligopeptides Proteins 0.000 description 4
239000004698 Polyethylene Substances 0.000 description 4
229920001213 Polysorbate 20 Polymers 0.000 description 4
229920002684 Sepharose Polymers 0.000 description 4
230000006052 T cell proliferation Effects 0.000 description 4
239000011324 bead Substances 0.000 description 4
244000309466 calf Species 0.000 description 4
230000022131 cell cycle Effects 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
208000029742 colonic neoplasm Diseases 0.000 description 4
230000007423 decrease Effects 0.000 description 4
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 4
229960002518 gentamicin Drugs 0.000 description 4
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
238000003306 harvesting Methods 0.000 description 4
238000009169 immunotherapy Methods 0.000 description 4
239000002245 particle Substances 0.000 description 4
239000008188 pellet Substances 0.000 description 4
239000013612 plasmid Substances 0.000 description 4
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
230000009870 specific binding Effects 0.000 description 4
238000010561 standard procedure Methods 0.000 description 4
239000000126 substance Substances 0.000 description 4
239000000758 substrate Substances 0.000 description 4
231100000617 superantigen Toxicity 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
230000003827 upregulation Effects 0.000 description 4
108091026890 Coding region Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
241000725303 Human immunodeficiency virus Species 0.000 description 3
206010025323 Lymphomas Diseases 0.000 description 3
101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 3
101100222220 Mus musculus Ctla4 gene Proteins 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
108020005067 RNA Splice Sites Proteins 0.000 description 3
206010039491 Sarcoma Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
108091008874 T cell receptors Proteins 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
239000000654 additive Substances 0.000 description 3
238000001042 affinity chromatography Methods 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
229940088710 antibiotic agent Drugs 0.000 description 3
210000000612 antigen-presenting cell Anatomy 0.000 description 3
230000007503 antigenic stimulation Effects 0.000 description 3
230000006907 apoptotic process Effects 0.000 description 3
238000013459 approach Methods 0.000 description 3
239000012298 atmosphere Substances 0.000 description 3
OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 3
239000000969 carrier Substances 0.000 description 3
230000010261 cell growth Effects 0.000 description 3
230000008859 change Effects 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
238000002512 chemotherapy Methods 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
230000009089 cytolysis Effects 0.000 description 3
230000002950 deficient Effects 0.000 description 3
230000003111 delayed effect Effects 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
231100000673 dose–response relationship Toxicity 0.000 description 3
238000004520 electroporation Methods 0.000 description 3
210000003743 erythrocyte Anatomy 0.000 description 3
239000000499 gel Substances 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
230000036039 immunity Effects 0.000 description 3
238000002513 implantation Methods 0.000 description 3
239000004816 latex Substances 0.000 description 3
229920000126 latex Polymers 0.000 description 3
230000000670 limiting effect Effects 0.000 description 3
239000012528 membrane Substances 0.000 description 3
210000004379 membrane Anatomy 0.000 description 3
230000001394 metastastic effect Effects 0.000 description 3
210000003205 muscle Anatomy 0.000 description 3
239000002831 pharmacologic agent Substances 0.000 description 3
210000004180 plasmocyte Anatomy 0.000 description 3
230000008569 process Effects 0.000 description 3
230000009696 proliferative response Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
230000000284 resting effect Effects 0.000 description 3
238000007423 screening assay Methods 0.000 description 3
230000028327 secretion Effects 0.000 description 3
239000006152 selective media Substances 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
229940054269 sodium pyruvate Drugs 0.000 description 3
238000010186 staining Methods 0.000 description 3
229960005322 streptomycin Drugs 0.000 description 3
230000007704 transition Effects 0.000 description 3
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
ZTOJFFHGPLIVKC-UHFFFAOYSA-N 3-ethyl-2-[(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound S1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C1=NN=C1SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-UHFFFAOYSA-N 0.000 description 2
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
206010003445 Ascites Diseases 0.000 description 2
241000283707 Capra Species 0.000 description 2
241000701022 Cytomegalovirus Species 0.000 description 2
238000012286 ELISA Assay Methods 0.000 description 2
102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 2
108700024394 Exon Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
208000032843 Hemorrhage Diseases 0.000 description 2
241000700721 Hepatitis B virus Species 0.000 description 2
208000017604 Hodgkin disease Diseases 0.000 description 2
101100005713 Homo sapiens CD4 gene Proteins 0.000 description 2
102000003839 Human Proteins Human genes 0.000 description 2
108090000144 Human Proteins Proteins 0.000 description 2
241000598436 Human T-cell lymphotropic virus Species 0.000 description 2
101150106931 IFNG gene Proteins 0.000 description 2
102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
206010062016 Immunosuppression Diseases 0.000 description 2
108010065805 Interleukin-12 Proteins 0.000 description 2
102000013462 Interleukin-12 Human genes 0.000 description 2
108010038453 Interleukin-2 Receptors Proteins 0.000 description 2
102000010789 Interleukin-2 Receptors Human genes 0.000 description 2
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
102000018697 Membrane Proteins Human genes 0.000 description 2
108010052285 Membrane Proteins Proteins 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
102100034256 Mucin-1 Human genes 0.000 description 2
108010008707 Mucin-1 Proteins 0.000 description 2
241001045988 Neogene Species 0.000 description 2
208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 2
208000009277 Neuroectodermal Tumors Diseases 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
102000004140 Oncostatin M Human genes 0.000 description 2
108090000630 Oncostatin M Proteins 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
208000037581 Persistent Infection Diseases 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
239000004365 Protease Substances 0.000 description 2
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
108091006629 SLC13A2 Proteins 0.000 description 2
241000700584 Simplexvirus Species 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
241000191940 Staphylococcus Species 0.000 description 2
230000024932 T cell mediated immunity Effects 0.000 description 2
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
101710120037 Toxin CcdB Proteins 0.000 description 2
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
210000000628 antibody-producing cell Anatomy 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000000740 bleeding effect Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
201000008275 breast carcinoma Diseases 0.000 description 2
230000003915 cell function Effects 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
230000003833 cell viability Effects 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
210000003679 cervix uteri Anatomy 0.000 description 2
239000007979 citrate buffer Substances 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000012790 confirmation Methods 0.000 description 2
238000010276 construction Methods 0.000 description 2
230000001086 cytosolic effect Effects 0.000 description 2
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
-1 dipstick Substances 0.000 description 2
230000002222 downregulating effect Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000012636 effector Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000012737 fresh medium Substances 0.000 description 2
238000002825 functional assay Methods 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
230000036541 health Effects 0.000 description 2
208000006454 hepatitis Diseases 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
239000007943 implant Substances 0.000 description 2
238000011534 incubation Methods 0.000 description 2
238000011081 inoculation Methods 0.000 description 2
229940117681 interleukin-12 Drugs 0.000 description 2
239000007928 intraperitoneal injection Substances 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
239000002502 liposome Substances 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
201000004792 malaria Diseases 0.000 description 2
239000003550 marker Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
206010061289 metastatic neoplasm Diseases 0.000 description 2
RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 2
229960002455 methoxyflurane Drugs 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
230000001114 myogenic effect Effects 0.000 description 2
229930014626 natural product Natural products 0.000 description 2
230000001338 necrotic effect Effects 0.000 description 2
101150091879 neo gene Proteins 0.000 description 2
230000000955 neuroendocrine Effects 0.000 description 2
201000011519 neuroendocrine tumor Diseases 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
150000002894 organic compounds Chemical class 0.000 description 2
230000037361 pathway Effects 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
102000013415 peroxidase activity proteins Human genes 0.000 description 2
108040007629 peroxidase activity proteins Proteins 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
230000001766 physiological effect Effects 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
238000012342 propidium iodide staining Methods 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
238000000159 protein binding assay Methods 0.000 description 2
230000005855 radiation Effects 0.000 description 2
238000001959 radiotherapy Methods 0.000 description 2
238000010188 recombinant method Methods 0.000 description 2
210000001350 reed-sternberg cell Anatomy 0.000 description 2
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
230000007017 scission Effects 0.000 description 2
235000004400 serine Nutrition 0.000 description 2
239000004017 serum-free culture medium Substances 0.000 description 2
241000894007 species Species 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 2
230000001573 trophoblastic effect Effects 0.000 description 2
208000029387 trophoblastic neoplasm Diseases 0.000 description 2
241001529453 unidentified herpesvirus Species 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
239000011782 vitamin Substances 0.000 description 2
235000013343 vitamin Nutrition 0.000 description 2
229930003231 vitamin Natural products 0.000 description 2
229940088594 vitamin Drugs 0.000 description 2
150000003722 vitamin derivatives Chemical class 0.000 description 2
238000005406 washing Methods 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
UHEPSJJJMTWUCP-DHDYTCSHSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N UHEPSJJJMTWUCP-DHDYTCSHSA-N 0.000 description 1
NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 1
102100023635 Alpha-fetoprotein Human genes 0.000 description 1
229930183010 Amphotericin Natural products 0.000 description 1
QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
102000006306 Antigen Receptors Human genes 0.000 description 1
108010083359 Antigen Receptors Proteins 0.000 description 1
108010035053 B7-1 Antigen Proteins 0.000 description 1
102000038504 B7-1 Antigen Human genes 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
238000011740 C57BL/6 mouse Methods 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282465 Canis Species 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
241001227713 Chiron Species 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
101710094648 Coat protein Proteins 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
102100036912 Desmin Human genes 0.000 description 1
108010044052 Desmin Proteins 0.000 description 1
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
101710091045 Envelope protein Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
206010015548 Euthanasia Diseases 0.000 description 1
241000282324 Felis Species 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
230000010190 G1 phase Effects 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
241000250507 Gigaspora candida Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
241000711549 Hepacivirus C Species 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
101100061678 Homo sapiens CTLA4 gene Proteins 0.000 description 1
101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
101000620359 Homo sapiens Melanocyte protein PMEL Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
241000701027 Human herpesvirus 6 Species 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
108010003272 Hyaluronate lyase Proteins 0.000 description 1
102000001974 Hyaluronidases Human genes 0.000 description 1
108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
241000283953 Lagomorpha Species 0.000 description 1
241000186781 Listeria Species 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
102100022430 Melanocyte protein PMEL Human genes 0.000 description 1
244000062730 Melissa officinalis Species 0.000 description 1
235000010654 Melissa officinalis Nutrition 0.000 description 1
241000699673 Mesocricetus auratus Species 0.000 description 1
241000713869 Moloney murine leukemia virus Species 0.000 description 1
240000002769 Morchella esculenta Species 0.000 description 1
235000002779 Morchella esculenta Nutrition 0.000 description 1
108090000143 Mouse Proteins Proteins 0.000 description 1
101000914483 Mus musculus T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
241000204031 Mycoplasma Species 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
208000005890 Neuroma Diseases 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
101710141454 Nucleoprotein Proteins 0.000 description 1
108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
241000577979 Peromyscus spicilegus Species 0.000 description 1
208000007452 Plasmacytoma Diseases 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
241000288906 Primates Species 0.000 description 1
101710083689 Probable capsid protein Proteins 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
102000007066 Prostate-Specific Antigen Human genes 0.000 description 1
108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
101710188315 Protein X Proteins 0.000 description 1
101150085390 RPM1 gene Proteins 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
208000007660 Residual Neoplasm Diseases 0.000 description 1
241000714474 Rous sarcoma virus Species 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
102000003800 Selectins Human genes 0.000 description 1
108090000184 Selectins Proteins 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
208000029033 Spinal Cord disease Diseases 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
102000004874 Synaptophysin Human genes 0.000 description 1
108090001076 Synaptophysin Proteins 0.000 description 1
208000000389 T-cell leukemia Diseases 0.000 description 1
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
206010042971 T-cell lymphoma Diseases 0.000 description 1
108700012920 TNF Proteins 0.000 description 1
241000223997 Toxoplasma gondii Species 0.000 description 1
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
230000000240 adjuvant effect Effects 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
238000013019 agitation Methods 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
108010026331 alpha-Fetoproteins Proteins 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229940009444 amphotericin Drugs 0.000 description 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
230000003416 augmentation Effects 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
239000003899 bactericide agent Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
210000004534 cecum Anatomy 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
125000003636 chemical group Chemical group 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
201000011024 colonic benign neoplasm Diseases 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
239000003636 conditioned culture medium Substances 0.000 description 1
210000000795 conjunctiva Anatomy 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
230000000139 costimulatory effect Effects 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
229940095074 cyclic amp Drugs 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
108010057085 cytokine receptors Proteins 0.000 description 1
238000004163 cytometry Methods 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
238000013461 design Methods 0.000 description 1
210000005045 desmin Anatomy 0.000 description 1
239000003599 detergent Substances 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
230000029087 digestion Effects 0.000 description 1
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
229960005156 digoxin Drugs 0.000 description 1
LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
239000000539 dimer Substances 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000007877 drug screening Methods 0.000 description 1
230000005584 early death Effects 0.000 description 1
230000000459 effect on growth Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000004696 endometrium Anatomy 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000006862 enzymatic digestion Effects 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
210000000744 eyelid Anatomy 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
239000005338 frosted glass Substances 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229960002743 glutamine Drugs 0.000 description 1
150000004676 glycans Chemical group 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
238000000227 grinding Methods 0.000 description 1
230000002949 hemolytic effect Effects 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
230000009215 host defense mechanism Effects 0.000 description 1
102000054189 human CD80 Human genes 0.000 description 1
229940084986 human chorionic gonadotropin Drugs 0.000 description 1
235000020256 human milk Nutrition 0.000 description 1
210000004251 human milk Anatomy 0.000 description 1
229960002773 hyaluronidase Drugs 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000012642 immune effector Substances 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000002998 immunogenetic effect Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000012606 in vitro cell culture Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
230000004068 intracellular signaling Effects 0.000 description 1
210000004153 islets of langerhan Anatomy 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
210000000867 larynx Anatomy 0.000 description 1
239000010410 layer Substances 0.000 description 1
239000000865 liniment Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
210000003810 lymphokine-activated killer cell Anatomy 0.000 description 1
231100000183 lymphotoxic Toxicity 0.000 description 1
230000001917 lymphotoxic effect Effects 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
239000006166 lysate Substances 0.000 description 1
239000006249 magnetic particle Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
239000011325 microbead Substances 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
102000035118 modified proteins Human genes 0.000 description 1
108091005573 modified proteins Proteins 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
239000000178 monomer Substances 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
229960000951 mycophenolic acid Drugs 0.000 description 1
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
230000007896 negative regulation of T cell activation Effects 0.000 description 1
230000025020 negative regulation of T cell proliferation Effects 0.000 description 1
230000017066 negative regulation of growth Effects 0.000 description 1
230000020402 negative regulation of interleukin-2 secretion Effects 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
230000036963 noncompetitive effect Effects 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
230000003071 parasitic effect Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
229940023041 peptide vaccine Drugs 0.000 description 1
239000000816 peptidomimetic Substances 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
210000004303 peritoneum Anatomy 0.000 description 1
230000035699 permeability Effects 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
108010031345 placental alkaline phosphatase Proteins 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
238000012809 post-inoculation Methods 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
210000004986 primary T-cell Anatomy 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
238000000746 purification Methods 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
230000009467 reduction Effects 0.000 description 1
201000010174 renal carcinoma Diseases 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
150000003355 serines Chemical class 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
239000002356 single layer Substances 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
239000002002 slurry Substances 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
230000003393 splenic effect Effects 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000003068 static effect Effects 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000003756 stirring Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
FRGKKTITADJNOE-UHFFFAOYSA-N sulfanyloxyethane Chemical compound CCOS FRGKKTITADJNOE-UHFFFAOYSA-N 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
230000002992 thymic effect Effects 0.000 description 1
208000008732 thymoma Diseases 0.000 description 1
230000009258 tissue cross reactivity Effects 0.000 description 1
210000002105 tongue Anatomy 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
239000003053 toxin Substances 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000010792 warming Methods 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1
229940075420 xanthine Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Zoology (AREA)
Mycology (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Endocrinology (AREA)
Virology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Radiation-Therapy Devices (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA2770851A 1995-12-04 1996-12-04 Blockade of t lymphocyte down-regulation associated with ctla-4 signaling Expired - Lifetime CA2770851C (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US08/566,853 US5855887A (en)	1995-07-25	1995-12-04	Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US08/566,853		1995-12-04
US08/646,605		1996-05-08
US08/646,605 US5811097A (en)	1995-07-25	1996-05-08	Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
CA2239448A CA2239448C (en)	1995-12-04	1996-12-04	Blockade of t lymphocyte down-regulation associated with ctla-4 signaling

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2239448A Division CA2239448C (en)	1995-12-04	1996-12-04	Blockade of t lymphocyte down-regulation associated with ctla-4 signaling

Publications (2)

Publication Number	Publication Date
CA2770851A1 CA2770851A1 (en)	1997-06-12
CA2770851C true CA2770851C (en)	2013-09-24

Family

ID=27074292

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CA2239448A Expired - Lifetime CA2239448C (en)	1995-12-04	1996-12-04	Blockade of t lymphocyte down-regulation associated with ctla-4 signaling
CA2770851A Expired - Lifetime CA2770851C (en)	1995-12-04	1996-12-04	Blockade of t lymphocyte down-regulation associated with ctla-4 signaling

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CA2239448A Expired - Lifetime CA2239448C (en)	1995-12-04	1996-12-04	Blockade of t lymphocyte down-regulation associated with ctla-4 signaling

Country Status (12)

Country	Link
US (1)	US5811097A (de)
EP (3)	EP2106800B1 (de)
JP (2)	JP4477701B2 (de)
AT (1)	ATE415172T1 (de)
AU (1)	AU730500B2 (de)
CA (2)	CA2239448C (de)
DE (2)	DE69637762D1 (de)
DK (2)	DK2332561T3 (de)
ES (2)	ES2579277T3 (de)
LU (1)	LU91927I2 (de)
PT (2)	PT865293E (de)
WO (1)	WO1997020574A1 (de)

Families Citing this family (532)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7597886B2 (en) *	1994-11-07	2009-10-06	Human Genome Sciences, Inc.	Tumor necrosis factor-gamma
US7820798B2 (en) *	1994-11-07	2010-10-26	Human Genome Sciences, Inc.	Tumor necrosis factor-gamma
US7429646B1 (en)	1995-06-05	2008-09-30	Human Genome Sciences, Inc.	Antibodies to human tumor necrosis factor receptor-like 2
US6051227A (en) *	1995-07-25	2000-04-18	The Regents Of The University Of California, Office Of Technology Transfer	Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US7888466B2 (en)	1996-01-11	2011-02-15	Human Genome Sciences, Inc.	Human G-protein chemokine receptor HSATU68
US6635743B1 (en)	1996-03-22	2003-10-21	Human Genome Sciences, Inc.	Apoptosis inducing molecule II and methods of use
US7964190B2 (en) *	1996-03-22	2011-06-21	Human Genome Sciences, Inc.	Methods and compositions for decreasing T-cell activity
US20060034844A1 (en) *	1996-12-04	2006-02-16	The Regents Of The University Of California	Stimulation of T cells against self antigens using CTLA-4 blocking agents
WO1998042752A1 (en) *	1997-03-21	1998-10-01	Brigham And Women's Hospital Inc.	Immunotherapeutic ctla-4 binding peptides
US6429286B1 (en) *	1997-04-16	2002-08-06	Juridical Foundation The Chemo-Sero-Therapeutic Research Institute	Immunoregulatory molecules for costimulatory signal transduction
EP1093457B8 (de)	1998-03-19	2011-02-02	Human Genome Sciences, Inc.	Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
JP5341287B2 (ja) *	1998-12-03	2013-11-13	ザリージェンツオブザユニバーシティオブカリフォルニア	Ｃｔｌａ−４遮断薬を用いる自己抗原に対するｔ細胞の刺激
US7109003B2 (en)	1998-12-23	2006-09-19	Abgenix, Inc.	Methods for expressing and recovering human monoclonal antibodies to CTLA-4
HRP20130077A2 (hr)	1998-12-23	2013-07-31	Pfizer Inc.	Humana monoklonalna protutjela za ctla-4
EE05627B1 (et) *	1998-12-23	2013-02-15	Pfizer Inc.	CTLA-4 vastased inimese monoklonaalsed antikehad
EP2357192A1 (de)	1999-02-26	2011-08-17	Human Genome Sciences, Inc.	Menschliches alpha-Endokin und Verfahren zu seiner Verwendung
US7605238B2 (en) *	1999-08-24	2009-10-20	Medarex, Inc.	Human CTLA-4 antibodies and their uses
CN102766210B (zh)	1999-08-24	2015-07-08	E.R.施贵宝&圣斯有限责任公司	人ctla-4抗体及其应用
EP1274720A4 (de)	2000-04-12	2004-08-18	Human Genome Sciences Inc	Albumin enthaltende fusionsproteine
US7700359B2 (en) *	2000-06-02	2010-04-20	Novartis Vaccines And Diagnostics, Inc.	Gene products differentially expressed in cancerous cells
WO2003057926A1 (en) *	2002-01-08	2003-07-17	Chiron Corporation	Gene products differentially expressed in cancerous breast cells and their methods of use
WO2001096528A2 (en)	2000-06-15	2001-12-20	Human Genome Sciences, Inc.	Human tumor necrosis factor delta and epsilon
EP1683865A3 (de)	2001-02-02	2006-10-25	Eli Lilly & Company	Säugerproteine und insbesondere CD200
WO2002064612A2 (en)	2001-02-09	2002-08-22	Human Genome Sciences, Inc.	Human g-protein chemokine receptor (ccr5) hdgnr10
DE60236646D1 (de)	2001-04-13	2010-07-22	Human Genome Sciences Inc	Anti-VEGF-2 Antikörper
IL149701A0 (en) *	2001-05-23	2002-11-10	Pfizer Prod Inc	Use of anti-ctla-4 antibodies
US6867189B2 (en) *	2001-07-26	2005-03-15	Genset S.A.	Use of adipsin/complement factor D in the treatment of metabolic related disorders
PT1463751E (pt)	2001-12-21	2013-08-26	Human Genome Sciences Inc	Proteínas de fusão de albumina
US6578724B1 (en) *	2001-12-29	2003-06-17	United States Can Company	Connector for use in packaging aerosol containers
ES2384168T3 (es)	2002-04-12	2012-07-02	Medarex, Inc.	Procedimientos de tratamiento usando anticuerpos CTLA-4
WO2003092624A2 (en) *	2002-05-02	2003-11-13	University Of Connecticut Health Center	Use of heat shock proteins to enhance efficacy of antibody therapeutics
MXPA05007615A (es) *	2003-01-21	2005-09-30	Bristol Myers Squibb Co	Polinucleotido que codifica una novedosa acil coenzima a, monoacilglicerol aciltransferasa-3 (mgat3), y usos del mismo.
CA2518782A1 (en) *	2003-03-12	2004-09-23	Duke University	Oligonucleotide mimetics
US8012681B2 (en)	2003-05-13	2011-09-06	Novartis Vaccines And Diagnostics, Inc.	Methods of modulating metastasis and skeletal related events resulting from metastases
US7465446B2 (en)	2003-05-30	2008-12-16	Medarex, Inc.	Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
JP5010923B2 (ja)	2004-02-09	2012-08-29	ヒューマンジノームサイエンシーズ，インコーポレイテッド	アルブミン融合蛋白質
CA2560919A1 (en) *	2004-03-26	2005-10-06	Pfizer Products Inc.	Uses of anti-ctla-4 antibodies
US7494779B2 (en) *	2004-06-14	2009-02-24	Li-Te Chin	Method for producing human antibodies to human CD152 with properties of agonist, antagonist, or inverse agonist
US20060057626A1 (en) *	2004-09-03	2006-03-16	Nichol Geoffrey M	Assessment of CTLA-4 polymorphisms in CTLA-4 blockade therapy
EP1793858A4 (de) *	2004-09-08	2008-12-10	Univ Ohio State Res Found	Menschliche monoklonale anti-ctla4-antikörper zur krebsbehandlung
BRPI0609427A2 (pt) *	2005-03-23	2010-04-06	Pfizer Prod Inc	composição farmacêutica para o tratamento de cáncer de próstata e uso de um agente de terapia hormonal e de um anticorpo, ou uma porção de ligação a antìgeno do mesmo
CN101146553A (zh) *	2005-03-23	2008-03-19	辉瑞产品公司	用于治疗癌症的抗-ctla4抗体和吲哚酮组合治疗
PL2161336T5 (pl)	2005-05-09	2017-10-31	Ono Pharmaceutical Co	Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
JP2008544746A (ja)	2005-05-12	2008-12-11	ザイモジェネティクス，インコーポレイテッド	免疫応答を調節するための組成物および方法
CA2612241C (en)	2005-07-01	2018-11-06	Medarex, Inc.	Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
NZ565172A (en)	2005-07-19	2012-12-21	Stemgen S P A	Inhibition of the tumorigenic potential of tumor stem cells by LIF and BMPS
US7943134B2 (en)	2005-08-31	2011-05-17	Academia Sinica	Compositions and methods for identifying response targets and treating flavivirus infection responses
TWI333959B (en) *	2005-08-31	2010-12-01	Academia Sinica	Methods and reagents for the analysis and purification of polysaccharides
CA2626082C (en)	2005-10-13	2017-04-11	Human Genome Sciences, Inc.	Methods and compositions for use in treatment of patients with autoantibody positive disease
ZA200804082B (en)	2005-11-07	2010-02-24	Scripps Research Inst	Compositions and methods for controlling tissue factor signaling specificity
JP2009514977A (ja) *	2005-11-08	2009-04-09	メダレックスインコーポレーティッド	免疫刺激性治療用抗体による治療に付随した腸炎に対するＴＮＦ−α遮断剤処置法
CN101325971A (zh)	2005-12-07	2008-12-17	米德列斯公司	Ctla-4抗体剂量递增方案
US9868961B2 (en) *	2006-03-30	2018-01-16	The Regents Of The University Of California	Methods and compositions for localized secretion of anti-CTLA-4 antibodies
US7572618B2 (en)	2006-06-30	2009-08-11	Bristol-Myers Squibb Company	Polynucleotides encoding novel PCSK9 variants
AU2007334264A1 (en)	2006-11-15	2008-06-26	Medarex, Inc.	Human monoclonal antibodies to BTLA and methods of use
US20100099090A1 (en) *	2007-03-05	2010-04-22	Bristol-Mayers Squibb Company	Biomarkers and methods for determining sensitivity to ctla-4 antagonists
CA2679986C (en) *	2007-03-08	2018-03-06	Martin Lackmann	Epha3 antibodies for the treatment of solid tumors
US7968300B2 (en) *	2007-11-21	2011-06-28	Li-Te Chin	Method of isolating regulatory T cells from human samples
KR20100100949A (ko)	2008-01-08	2010-09-15	브리스톨-마이어스 스큅 컴퍼니	증식성 질환의 치료를 위한 튜불린 조정제와 항-ｃｔｌａ４ 항체의 조합물
DE202008000834U1 (de)	2008-01-21	2008-05-29	Chin, Li-Te	Zusammensetzung und Reagenz für CTLA-4 und Verwendungen derselben
US20110020368A1 (en)	2008-03-25	2011-01-27	Nancy Hynes	Treating cancer by down-regulating frizzled-4 and/or frizzled-1
WO2009148915A2 (en) *	2008-05-29	2009-12-10	Bristol-Myers Squibb Company	Methods for predicting patient response to modulation of the co-stimulatory pathway
WO2010014784A2 (en)	2008-08-01	2010-02-04	Bristol-Myers Squibb Company	Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
AR072999A1 (es)	2008-08-11	2010-10-06	Medarex Inc	Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010042433A1 (en)	2008-10-06	2010-04-15	Bristol-Myers Squibb Company	Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
EP2241323A1 (de)	2009-04-14	2010-10-20	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Tenascin-W und Hirnkrebs
US20100297072A1 (en) *	2009-05-19	2010-11-25	Depinho Ronald A	Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
LT2769737T (lt)	2009-07-20	2017-06-26	Bristol-Myers Squibb Company	Anti-ctla4 antikūno derinys su etopozidu, skirtas sinerginiam proliferacinių ligų gydymui
EP2292266A1 (de)	2009-08-27	2011-03-09	Novartis Forschungsstiftung, Zweigniederlassung	Behandlung von Krebs durch Modulation von Copine III
US20120244170A1 (en)	2009-09-22	2012-09-27	Rafal Ciosk	Treating cancer by modulating mex-3
WO2011045352A2 (en)	2009-10-15	2011-04-21	Novartis Forschungsstiftung	Spleen tyrosine kinase and brain cancers
US20120213801A1 (en)	2009-10-30	2012-08-23	Ekaterina Gresko	Phosphorylated Twist1 and cancer
WO2011107586A1 (en)	2010-03-05	2011-09-09	Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research,	Smoc1, tenascin-c and brain cancers
US20150231215A1 (en)	2012-06-22	2015-08-20	Randolph J. Noelle	VISTA Antagonist and Methods of Use
US10745467B2 (en)	2010-03-26	2020-08-18	The Trustees Of Dartmouth College	VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
MX342017B (es)	2010-03-26	2016-09-09	Dartmouth College	Proteina mediadora de celula t regulatoria vista, agentes de enlace de vista y uso de los mismos.
US20130034543A1 (en)	2010-04-19	2013-02-07	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear	Modulating xrn1
US20130064831A1 (en)	2010-05-17	2013-03-14	Bristol-Myers Squibb Company	Immunotherapeutic dosing regimens and combinations thereof
WO2011154485A1 (en)	2010-06-10	2011-12-15	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Treating cancer by modulating mammalian sterile 20-like kinase 3
EP2614080A1 (de)	2010-09-10	2013-07-17	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Phosphoryliertes twist1 und metastasen
EP2701699B1 (de)	2011-04-28	2019-10-16	The Broad Institute, Inc.	Histondeacetylase-hemmer
EP2717911A1 (de)	2011-06-06	2014-04-16	Novartis Forschungsstiftung, Zweigniederlassung	Proteintyrosinphosphatase, nicht-rezeptor typ 11 (ptpn11) und dreifach negativer brustkrebs
CA2850575C (en) *	2011-10-11	2020-12-15	Universitat Zurich Prorektorat Mnw	Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy
US11951157B2 (en)	2011-10-11	2024-04-09	Universitat Zurich	Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody
EP2591796A1 (de) *	2011-11-10	2013-05-15	Universität Zürich	Kombinationsmedikament umfassend IL-12 und einen anti-CTLA-4-Liganden zur Tumortherapie
US20140294732A1 (en)	2011-11-08	2014-10-02	Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute	Early diagnostic of neurodegenerative diseases
EP2776022A1 (de)	2011-11-08	2014-09-17	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Neue behandlung für neurodegenerative erkrankungen
EP2800583A1 (de)	2012-01-02	2014-11-12	Novartis AG	Cdcp1 und brustkrebs
WO2013138702A2 (en)	2012-03-15	2013-09-19	Bristol-Myers Squibb Company	Methods for predicting gastrointestinal immune-related adverse events (gi-irae) in patients treated with modulation of the co-stimulatory pathway
WO2013142796A2 (en)	2012-03-23	2013-09-26	Bristol-Myers Squibb Company	Methods of treatments using ctla4 antibodies
EP2831112A1 (de)	2012-03-29	2015-02-04	Friedrich Miescher Institute for Biomedical Research	Hemmung von interleukin 8 und/oder dessen rezeptor cxcrl bei der behandlung von brustkrebs mit her2/her3-überexpression
US20150118244A1 (en)	2012-05-10	2015-04-30	Bristol-Myers Squibb Company	Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
CN104619722B (zh)	2012-06-22	2022-10-04	达特茅斯大学理事会	新型vista-ig构建体和vista-ig用于治疗自身免疫性、过敏性和炎性疾病的用途
US9890215B2 (en)	2012-06-22	2018-02-13	King's College London	Vista modulators for diagnosis and treatment of cancer
WO2014001482A1 (en)	2012-06-29	2014-01-03	Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research	Treating diseases by modulating a specific isoform of mkl1
UY34887A (es)	2012-07-02	2013-12-31	Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware	Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
WO2014006114A1 (en)	2012-07-05	2014-01-09	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	New treatment for neurodegenerative diseases
US20150224190A1 (en)	2012-07-06	2015-08-13	Mohamed Bentires-Alj	Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction
JP6337255B2 (ja)	2012-07-27	2018-06-06	ザブロードインスティテュート, インコーポレーテッドThe Broad Institute, Inc.	ヒストンデアセチラーゼの阻害剤
FI3381942T4 (fi)	2012-08-30	2025-12-16	Amgen Inc	Menetelmä melanooman hoitamiseksi herpes simplex -virusta ja immuuniaktivaation vapauttajaa käyttäen
CA2884704C (en)	2012-09-07	2023-04-04	Randolph J. Noelle	Vista modulators for diagnosis and treatment of cancer
TWI664976B (zh)	2013-01-02	2019-07-11	美商迪科生物系統公司	使用細菌治療癌症之組成物和方法
US9308236B2 (en)	2013-03-15	2016-04-12	Bristol-Myers Squibb Company	Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
ES2761587T3 (es)	2013-08-07	2020-05-20	Friedrich Miescher Institute For Biomedical Res	Nuevo método de cribado para el tratamiento de la ataxia de Friedreich
SI3030262T1 (sl)	2013-08-08	2020-03-31	Cytune Pharma	Kombiniran farmacevtski sestavek
CA2919725C (en)	2013-08-08	2023-04-18	Cytune Pharma	An il-15 and il-15r.aplha. sushi domain based modulokines
AU2014323523B2 (en)	2013-09-20	2020-02-20	Bristol-Myers Squibb Company	Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
EP3757130A1 (de)	2013-09-26	2020-12-30	Costim Pharmaceuticals Inc.	Verfahren zur behandlung von blutkrebs
IL292510A (en)	2013-11-05	2022-06-01	Cognate Bioservices Inc	Combinations of checkpoint inhibitors and therapeutics to treat cancer
EP3066127A1 (de)	2013-11-06	2016-09-14	Bristol-Myers Squibb Company	Pläne zur immuntherapeutischen dosierung und kombinationen davon
US11014987B2 (en)	2013-12-24	2021-05-25	Janssen Pharmaceutics Nv	Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
EP4043493A1 (de)	2013-12-24	2022-08-17	Janssen Pharmaceutica NV	Anti-vista-antikörper und -fragmente
CA2935423C (en)	2014-01-24	2023-11-07	Dana-Farber Cancer Institute, Inc.	Antibody molecules to pd-1 and uses thereof
AU2015210750B2 (en)	2014-01-31	2020-08-20	Children's Medical Center Corporation	Antibody molecules to TIM-3 and uses thereof
WO2015138920A1 (en)	2014-03-14	2015-09-17	Novartis Ag	Antibody molecules to lag-3 and uses thereof
US9850225B2 (en)	2014-04-14	2017-12-26	Bristol-Myers Squibb Company	Compounds useful as immunomodulators
AU2015271709B2 (en)	2014-06-06	2020-11-26	Bristol-Myers Squibb Company	Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
EP3154585B1 (de)	2014-06-11	2022-02-23	Kathy A. Green	Verwendung von vista-agonisten und antagonisten zur unterdrückung oder verbesserung der humoralen immunität
EP3154579A1 (de)	2014-06-13	2017-04-19	Friedrich Miescher Institute for Biomedical Research	Neue behandlung gegen das influenzavirus
US10308935B2 (en)	2014-06-23	2019-06-04	Friedrich Miescher Institute For Biomedical Research	Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small RNAS
US20170165261A1 (en)	2014-07-01	2017-06-15	Brian Arthur Hemmings	Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
US10765710B2 (en)	2014-07-16	2020-09-08	Institut Gustave-Roussy	Combination of oncolytic virus with immune checkpoint modulators
EP3552615B8 (de)	2014-07-16	2022-03-02	Transgene	Onkolytisches virus zur expression von immunologischen prüfpunktmodulatoren
CN105296433B (zh)	2014-08-01	2018-02-09	中山康方生物医药有限公司	一种ctla4抗体、其药物组合物及其用途
WO2016040882A1 (en)	2014-09-13	2016-03-17	Novartis Ag	Combination therapies of egfr inhibitors
EP3197557A1 (de)	2014-09-24	2017-08-02	Friedrich Miescher Institute for Biomedical Research	Lats und brustrkrebs
KR20170066546A (ko)	2014-10-03	2017-06-14	노파르티스 아게	조합 요법
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
WO2016057898A1 (en)	2014-10-10	2016-04-14	Idera Pharmaceuticals, Inc.	Treatment of cancer using tlr9 agonist with checkpoint inhibitors
US9732119B2 (en)	2014-10-10	2017-08-15	Bristol-Myers Squibb Company	Immunomodulators
WO2016061142A1 (en)	2014-10-14	2016-04-21	Novartis Ag	Antibody molecules to pd-l1 and uses thereof
US9856292B2 (en)	2014-11-14	2018-01-02	Bristol-Myers Squibb Company	Immunomodulators
TWI711630B (zh)	2014-11-21	2020-12-01	美商必治妥美雅史谷比公司	抗ｃｄ７３抗體及其用途
US20170355768A1 (en)	2014-12-04	2017-12-14	Bristol-Myers Squibb Company	Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)
JP2018505911A (ja)	2014-12-05	2018-03-01	イミュネクスト，インコーポレーテッド	推定上のｖｉｓｔａ受容体としてのｖｓｉｇ８の同定と、ｖｉｓｔａ／ｖｓｉｇ８調節剤を産生するためのその使用
JP6767096B2 (ja)	2014-12-11	2020-10-14	リティックスバイオファーマエイエス	免疫チェックポイント阻害剤の組み合わせ
WO2016100364A1 (en)	2014-12-18	2016-06-23	Amgen Inc.	Stable frozen herpes simplex virus formulation
US9861680B2 (en)	2014-12-18	2018-01-09	Bristol-Myers Squibb Company	Immunomodulators
US9944678B2 (en)	2014-12-19	2018-04-17	Bristol-Myers Squibb Company	Immunomodulators
EP3233918A1 (de)	2014-12-19	2017-10-25	Novartis AG	Kombinationstherapien
MY187045A (en)	2014-12-23	2021-08-27	Bristol Myers Squibb Co	Antibodies to tigit
US20180215801A1 (en)	2015-01-29	2018-08-02	Board Of Trustees Of Michigan State University	Cryptic polypeptides and uses thereof
US20160222060A1 (en)	2015-02-04	2016-08-04	Bristol-Myers Squibb Company	Immunomodulators
ES3011733T3 (en)	2015-02-13	2025-04-08	Transgene	Immunotherapeutic vaccine and antibody combination therapy
SG11201706583PA (en)	2015-02-19	2017-09-28	Compugen Ltd	Anti-pvrig antibodies and methods of use
JO3746B1 (ar)	2015-03-10	2021-01-31	Aduro Biotech Inc	تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
WO2016146143A1 (en)	2015-03-16	2016-09-22	Amal Therapeutics Sa	Cell penetrating peptides and complexes comprising the same
US9809625B2 (en)	2015-03-18	2017-11-07	Bristol-Myers Squibb Company	Immunomodulators
EP3273974A4 (de)	2015-03-26	2018-11-07	Women and Infants Hospital of Rhode Island Inc.	Therapie für maligne erkrankungen
EP3281010B1 (de)	2015-04-10	2020-12-30	The Regents of The University of California	Verfahren zur bestimmung von auf immunmodulatorische behandlung von krebs ansprechenden patientenpopulationen
EP3294334B1 (de)	2015-05-11	2020-07-08	The Johns Hopkins University	Autoimmunantikörper zur verwendung bei der hemmung des wachstums von krebszellen
MX383614B (es)	2015-05-21	2025-03-14	Harpoon Therapeutics Inc	Proteinas de union triespecificas y metodos de uso.
CA3176224A1 (en)	2015-05-22	2016-12-01	Translational Drug Development Llc	Benzamide and active compound compositions and methods of use
CA2986765A1 (en)	2015-05-29	2016-12-08	Agenus Inc.	Anti-ctla-4 antibodies and methods of use thereof
EA035412B1 (ru)	2015-05-29	2020-06-10	Бристол-Майерс Сквибб Компани	Антитела к ox40 и их применение
TWI773646B (zh)	2015-06-08	2022-08-11	美商宏觀基因股份有限公司	結合lag-3的分子和其使用方法
EP3722314A1 (de)	2015-06-24	2020-10-14	Janssen Pharmaceutica NV	Anti-vista-antikörper und -fragmente
SI3313528T1 (sl)	2015-06-29	2021-11-30	Bristol-Myers Squibb Company	Imunoterapevtski režim odmerjanja, ki vsebujejo pomalidomid in protitelo anti-CS1 za zdravljenje raka
US10479838B2 (en)	2015-06-29	2019-11-19	Bristol-Myers Squibb Company	Antibodies to CD40 with enhanced agonist activity
WO2017004532A1 (en)	2015-07-02	2017-01-05	Celgene Corporation	Combination therapy for treatment of hematological cancers and solid tumors
EP3744340A3 (de)	2015-07-16	2021-03-03	Biokine Therapeutics Ltd.	Zusammensetzungen und verfahren zur behandlung von krebs
CN116059219A (zh)	2015-07-16	2023-05-05	比奥克斯塞尔医疗股份有限公司	一种使用免疫调节治疗癌症的新颖方法
WO2017019897A1 (en)	2015-07-29	2017-02-02	Novartis Ag	Combination therapies comprising antibody molecules to tim-3
EP4378957A3 (de)	2015-07-29	2024-08-07	Novartis AG	Kombinationstherapien mit antikörpermolekülen gegen pd-1
ES2878188T3 (es)	2015-07-29	2021-11-18	Novartis Ag	Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
AU2016298227B9 (en)	2015-07-30	2019-10-31	Macrogenics, Inc.	PD-1-binding molecules and methods of use thereof
US10660954B2 (en)	2015-07-31	2020-05-26	University Of Florida Research Foundation, Incorporated	Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer
EP3331917A1 (de)	2015-08-04	2018-06-13	GlaxoSmithKline Intellectual Property Development Limited	Kombinationsbehandlungen sowie verwendungen und verfahren davon
EP3331919A1 (de)	2015-08-07	2018-06-13	GlaxoSmithKline Intellectual Property Development Limited	Kombinationstherapie mit anti-ctla-4-antikörpern
EP3341732B1 (de)	2015-08-27	2023-07-12	INSERM - Institut National de la Santé et de la Recherche Médicale	Verfahren zur vorhersage der überlebenszeit von patienten mit lungenkrebs
RU2638457C2 (ru)	2015-09-28	2017-12-13	Общество С Ограниченной Ответственностью "Онкомакс"	Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
WO2017055327A1 (en)	2015-09-29	2017-04-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for quantifying the population of endothelial cells in a tissue sample
WO2017055326A1 (en)	2015-09-29	2017-04-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for quantifying the population of myeloid dendritic cells in a tissue sample
WO2017055324A1 (en)	2015-09-29	2017-04-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for quantifying the population of cells of monocytic origin in a tissue sample
WO2017055321A1 (en)	2015-09-29	2017-04-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for quantifying the population of fibroblasts in a tissue sample
WO2017055320A1 (en)	2015-09-29	2017-04-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample
WO2017055322A1 (en)	2015-09-29	2017-04-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for quantifying the population of neutrophils in a tissue sample
WO2017055319A1 (en)	2015-09-29	2017-04-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for quantifying the population of b cells in a tissue sample
WO2017055325A1 (en)	2015-09-29	2017-04-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for quantifying the population of nk cells in a tissue sample
WO2017060397A1 (en)	2015-10-09	2017-04-13	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting the survival time of subjects suffering from melanoma metastases
US10745382B2 (en)	2015-10-15	2020-08-18	Bristol-Myers Squibb Company	Compounds useful as immunomodulators
CN108135934B (zh)	2015-10-19	2024-09-10	永恒生物科技股份有限公司	通过组合疗法治疗实体或淋巴肿瘤的方法
US10149887B2 (en)	2015-10-23	2018-12-11	Canbas Co., Ltd.	Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
US20180348224A1 (en)	2015-10-28	2018-12-06	Friedrich Miescher Institute For Biomedical Resear Ch	Tenascin-w and biliary tract cancers
CA3005855A1 (en)	2015-11-19	2017-05-26	Bristol-Myers Squibb Company	Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
JP6955507B2 (ja)	2015-12-14	2021-10-27	マクロジェニクス，インコーポレーテッド	Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法
EP3389712B1 (de)	2015-12-17	2024-04-10	Novartis AG	Antikörpermoleküle gegen pd-1 und verwendungen davon
MX385964B (es)	2016-01-08	2025-03-18	Celgene Corp	Formas sólidas de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il) metil)-2,2-difluoroacetamida y sus composiciones farmacéuticas y usos.
BR112018013884A2 (pt)	2016-01-08	2018-12-18	Celgene Corp	formulações de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
EP3399978B1 (de)	2016-01-08	2020-09-09	Celgene Corporation	Antiproliferative verbindungen und deren pharmazeutische zusammensetzungen und verwendungen
HK1257518A1 (zh)	2016-01-11	2019-10-25	Novartis Ag	针对人白介素-2的免疫刺激性人源化单克隆抗体及其融合蛋白
WO2017129769A1 (en)	2016-01-28	2017-08-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for enhancing the potency of the immune checkpoint inhibitors
EP4035681A1 (de)	2016-01-28	2022-08-03	Institut National de la Santé et de la Recherche Médicale (INSERM)	Verfahren und pharmazeutische zusammensetzung zur behandlung von krebs
TW202216201A (zh)	2016-02-12	2022-05-01	比利時商楊森製藥公司	抗vista抗體及片段、其用途及鑑定其之方法
CA3013333A1 (en)	2016-02-26	2017-08-31	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Antibodies having specificity for btla and uses thereof
CA3016187A1 (en)	2016-03-04	2017-09-08	Bristol-Myers Squibb Company	Combination therapy with anti-cd73 antibodies
KR20180114223A (ko)	2016-03-04	2018-10-17	더 락커펠러 유니버시티	증진된 효능제 활성을 갖는 cd40에 대한 항체
US10143746B2 (en)	2016-03-04	2018-12-04	Bristol-Myers Squibb Company	Immunomodulators
ES3041500T3 (en)	2016-03-10	2025-11-12	Cg Oncology Inc	Methods of treating solid tumors by combination therapy
WO2017160599A1 (en)	2016-03-14	2017-09-21	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Use of cd300b antagonists to treat sepsis and septic shock
BR112018068461A2 (pt)	2016-03-15	2019-01-22	Mersana Therapeutics Inc	conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer.
PT3429618T (pt)	2016-03-16	2024-04-02	Amal Therapeutics Sa	Combinação de um modulador de ponto de controlo imunitário e um complexo que compreende um péptido de penetração celular, uma carga e um agonistra peptídico de tlr para utilização em medicina
US10358463B2 (en)	2016-04-05	2019-07-23	Bristol-Myers Squibb Company	Immunomodulators
SG11201808909WA (en)	2016-04-13	2018-11-29	Vivia Biotech Sl	Ex vivo bite-activated t cells
JP7184751B2 (ja)	2016-04-15	2022-12-06	イミュネクストインコーポレイテッド	抗ヒトｖｉｓｔａ抗体およびその使用
US20190298824A1 (en)	2016-05-04	2019-10-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv	Albumin-binding immunomodulatory compositions and methods of use thereof
DK3458083T5 (da)	2016-05-18	2024-10-21	Modernatx Inc	Polynukleotider, der koder for interleukin-12 (il12), og anvendelser heraf
EP3458485B1 (de)	2016-05-19	2021-12-29	The General Hospital Corporation	An den rezeptor il-2rbeta gebundenes interleukin-2, eine plattform zur erhöhung der aktivität von natürlichen killer- und regulatorischen t-zellen
US11623958B2 (en)	2016-05-20	2023-04-11	Harpoon Therapeutics, Inc.	Single chain variable fragment CD3 binding proteins
US10100106B2 (en)	2016-05-20	2018-10-16	Harpoon Therapeutics, Inc.	Single domain serum albumin binding protein
KR20190032295A (ko)	2016-05-25	2019-03-27	인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)	암 치료 방법 및 조성물
WO2017210181A1 (en)	2016-05-30	2017-12-07	Geovax Inc.	Compositions and methods for generating an immune response to hepatitis b virus
MX391135B (es)	2016-06-24	2025-03-21	Infinity Pharmaceuticals Inc	Terapias de combinacion.
CN109983121A (zh)	2016-06-30	2019-07-05	昂克诺斯公司	治疗性多肽的假型化溶瘤病毒递送
EP3507367A4 (de)	2016-07-05	2020-03-25	Aduro BioTech, Inc.	Cyclisches dinukleotidverbindungen mit eingeschlossenen nukleinsäuren und verwendungen davon
KR102491992B1 (ko)	2016-07-08	2023-01-25	브리스톨-마이어스 스큅 컴퍼니	면역조정제로서 유용한 1,3-디히드록시-페닐 유도체
WO2018011166A2 (en)	2016-07-12	2018-01-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for quantifying the population of myeloid dendritic cells in a tissue sample
SG11201900026TA (en)	2016-07-14	2019-01-30	Bristol Myers Squibb Co	Antibodies against tim3 and uses thereof
US11649289B2 (en)	2016-08-04	2023-05-16	Glaxosmithkline Intellectual Property Development Limited	Anti-ICOS and anti-PD-1 antibody combination therapy
WO2018029336A1 (en)	2016-08-12	2018-02-15	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway.
US11225689B2 (en)	2016-08-17	2022-01-18	The Broad Institute, Inc.	Method for determination and identification of cell signatures and cell markers
AU2017313085B2 (en)	2016-08-19	2024-06-20	Beone Medicines I Gmbh	Use of a combination comprising a Btk inhibitor for treating cancers
WO2018035710A1 (en)	2016-08-23	2018-03-01	Akeso Biopharma, Inc.	Anti-ctla4 antibodies
US10144706B2 (en)	2016-09-01	2018-12-04	Bristol-Myers Squibb Company	Compounds useful as immunomodulators
CN109906082A (zh)	2016-09-07	2019-06-18	塔夫茨大学信托人	使用免疫dash抑制剂和pge2拮抗剂的组合治疗
WO2018046738A1 (en)	2016-09-12	2018-03-15	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting the survival time of patients suffering from cancer
WO2018046736A1 (en)	2016-09-12	2018-03-15	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting the survival time of patients suffering from cancer
IL265479B (en)	2016-09-21	2022-09-01	Amal Therapeutics Sa	A fusion containing a cell-penetrating peptide, a multiple epitope, and a peptide tlr agonist for cancer therapy
WO2018055080A1 (en)	2016-09-22	2018-03-29	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof
CN109906232B (zh)	2016-09-23	2023-11-07	马伦戈治疗公司	包含λ轻链和κ轻链的多特异性抗体分子
WO2018067991A1 (en)	2016-10-07	2018-04-12	The Brigham And Women's Hospital, Inc.	Modulation of novel immune checkpoint targets
EP3535280B1 (de)	2016-11-07	2022-03-16	Bristol-Myers Squibb Company	Immunomodulatoren
WO2018087391A1 (en)	2016-11-14	2018-05-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for modulating stem cells proliferation or differentiation
AU2017363337B2 (en)	2016-11-23	2021-07-01	Translational Drug Development, Llc	Benzamide and active compound compositions and methods of use
US11135307B2 (en)	2016-11-23	2021-10-05	Mersana Therapeutics, Inc.	Peptide-containing linkers for antibody-drug conjugates
WO2018099539A1 (en)	2016-11-29	2018-06-07	Horst Lindhofer	Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof
WO2018100534A1 (en)	2016-12-01	2018-06-07	Glaxosmithkline Intellectual Property Development Limited	Combination therapy
BR112019011350A2 (pt)	2016-12-01	2019-10-22	Glaxosmithkline Ip Dev Ltd	terapia de combinação
FI3551660T3 (fi)	2016-12-07	2023-12-11	Agenus Inc	Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä
WO2018112360A1 (en)	2016-12-16	2018-06-21	Evelo Biosciences, Inc.	Combination therapies for treating cancer
JP7106572B2 (ja)	2016-12-20	2022-07-26	ブリストル－マイヤーズスクイブカンパニー	免疫調節剤として有用な化合物
JP2020501589A (ja)	2016-12-23	2020-01-23	ウイルツ・バイオロジクス・リミテッド	がんの治療
WO2018122249A1 (en)	2016-12-28	2018-07-05	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer
WO2018122245A1 (en)	2016-12-28	2018-07-05	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of predicting the survival time of patients suffering from cms3 colorectal cancer
EP3564678A4 (de)	2016-12-28	2020-08-12	Kinki University	Verfahren zur auswahl von personen zur verabreichung eines immuncheckpoint-inhibitors
US11377497B2 (en)	2017-01-23	2022-07-05	Suzhou Alphamab Co., Ltd.	PD-L1 binding polypeptide or composite
EP3573979A1 (de)	2017-01-27	2019-12-04	Celgene Corporation	3-(1-oxo-4-((4-((3-oxomorpholino)-methyl)benzyl)oxy)isoindolin-2-yl)piperidin-2,6-dion und isotopologe davon
WO2018146148A1 (en)	2017-02-07	2018-08-16	INSERM (Institut National de la Santé et de la Recherche Médicale)	A method for predicting the response to checkpoint blockade cancer immunotherapy
US11229668B2 (en)	2017-02-07	2022-01-25	Nantcell, Inc.	Maximizing T-cell memory and compositions and methods therefor
WO2018146128A1 (en)	2017-02-07	2018-08-16	INSERM (Institut National de la Santé et de la Recherche Médicale)	Detection of kit polymorphism for predicting the response to checkpoint blockade cancer immunotherapy
WO2018151820A1 (en)	2017-02-16	2018-08-23	Elstar Therapeutics, Inc.	Multifunctional molecules comprising a trimeric ligand and uses thereof
WO2018160538A1 (en)	2017-02-28	2018-09-07	Mersana Therapeutics, Inc.	Combination therapies of her2-targeted antibody-drug conjugates
MX2019009660A (es)	2017-02-28	2019-10-02	Bristol Myers Squibb Co	Uso de anticuerpos antigeno 4 del linfocito t (ctla-4) con citotoxicidad celular dependiente de anticuerpos (adcc) mejorada para mejorar la respuesta inmune a una vacuna.
WO2018167780A1 (en)	2017-03-12	2018-09-20	Yeda Research And Development Co. Ltd.	Methods of prognosing and treating cancer
WO2018167778A1 (en)	2017-03-12	2018-09-20	Yeda Research And Development Co. Ltd.	Methods of diagnosing and prognosing cancer
MX2019010797A (es)	2017-03-15	2019-10-24	Amgen Inc	Uso de virus oncoliticos, solos o en combinacion con un inhibidor de punto de control, para el tratamiento del cancer.
WO2018175924A1 (en)	2017-03-24	2018-09-27	The Broad Institute, Inc.	Methods and compositions for regulating innate lymphoid cell inflammatory responses
JP7150745B2 (ja)	2017-03-27	2022-10-11	ブリストル－マイヤーズスクイブカンパニー	免疫調節剤としての置換イソキノリン誘導体
US11913075B2 (en)	2017-04-01	2024-02-27	The Broad Institute, Inc.	Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
KR20200020662A (ko)	2017-04-03	2020-02-26	온콜로지, 인크.	면역-종양학 제제와 함께 ps-표적화 항체를 사용하여 암을 치료하는 방법
WO2018191558A1 (en)	2017-04-12	2018-10-18	The Broad Institute, Inc.	Modulation of epithelial cell differentiation, maintenance and/or function through t cell action, and markers and methods of use thereof
JP2020517256A (ja)	2017-04-19	2020-06-18	エルスターセラピューティクス，インコーポレイテッド	多重特異性分子およびその使用
AU2018254626B2 (en)	2017-04-21	2023-12-21	Sillajen, Inc.	Oncolytic vaccinia virus and checkpoint inhibitor combination therapy
MX2019012741A (es)	2017-04-28	2020-01-21	Merck Sharp & Dohme	Biomarcadores para agentes terapeuticos contra el cancer.
UY37695A (es)	2017-04-28	2018-11-30	Novartis Ag	Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
EP4328241A3 (de)	2017-04-28	2024-06-05	Marengo Therapeutics, Inc.	Multispezifische moleküle mit einer nichtimmunglobulin-heterodimerisierungsdomäne und verwendungen davon
WO2018209324A2 (en)	2017-05-11	2018-11-15	The Broad Institute, Inc.	Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
AU2018265856B2 (en)	2017-05-12	2023-04-27	Harpoon Therapeutics, Inc.	Mesothelin binding proteins
CA3060984A1 (en)	2017-05-30	2018-12-06	Bristol-Myers Squibb Company	Treatment of lag-3 positive tumors
KR102721137B1 (ko)	2017-05-30	2024-10-25	브리스톨-마이어스 스큅 컴퍼니	항-lag-3 항체 또는 항-lag-3 항체 및 항-pd-1 또는 항-pd-l1 항체를 포함하는 조성물
WO2018222901A1 (en)	2017-05-31	2018-12-06	Elstar Therapeutics, Inc.	Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
JP2020522498A (ja)	2017-06-01	2020-07-30	ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、Ｉｎｃ．	Ｃｄ１２３ｃｄ３に結合する二重特異性抗体
WO2018223004A1 (en)	2017-06-01	2018-12-06	Xencor, Inc.	Bispecific antibodies that bind cd20 and cd3
AU2018281830B2 (en)	2017-06-09	2023-11-02	Agonox, Inc.	Utilization of CD39 and CD103 for identification of human tumor reactive cells for treatment of cancer
KR102772810B1 (ko) *	2017-06-15	2025-02-28	캔서 어드밴시스 아이엔씨	종양 및 암에 대한 체액성 및 세포 면역을 유도하기 위한 조성물 및 방법
EP3641739A1 (de)	2017-06-20	2020-04-29	Institut Curie	Inhibitor der suv39h1-histonmethyltransferase zur verwendung in der krebskombinationstherapie
ES2959860T3 (es)	2017-06-22	2024-02-28	Celgene Corp	Tratamiento del carcinoma hepatocelular caracterizado por la infección por el virus de la hepatitis B
KR102735038B1 (ko)	2017-06-23	2024-11-28	브리스톨-마이어스 스큅 컴퍼니	Pd-1의 길항제로서 작용하는 면역조정제
PL3644999T3 (pl)	2017-06-30	2023-05-08	Celgene Corporation	Kompozycje i sposoby zastosowania 2-(4-chlorofenylo)-n-((2-(2,6-dioksopiperydyn-3-ylo)-1-oksoizoindolin-5-ylo)metylo)-2,2-difluoroacetamidu
JP7258009B2 (ja)	2017-07-10	2023-04-14	セルジーンコーポレイション	抗増殖化合物及びその使用方法
US12049643B2 (en)	2017-07-14	2024-07-30	The Broad Institute, Inc.	Methods and compositions for modulating cytotoxic lymphocyte activity
US12105089B2 (en)	2017-07-17	2024-10-01	The Broad Institute, Inc.	Cell atlas of the healthy and ulcerative colitis human colon
WO2019020593A1 (en)	2017-07-25	2019-01-31	INSERM (Institut National de la Santé et de la Recherche Médicale)	METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATION OF MONOCYTOPOISIS
WO2019035938A1 (en)	2017-08-16	2019-02-21	Elstar Therapeutics, Inc.	MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
US20210060158A1 (en)	2017-09-19	2021-03-04	Institut Curie	Agonist of aryl hydrocarbon receptor for use in cancer combination therapy
WO2019070755A1 (en)	2017-10-02	2019-04-11	The Broad Institute, Inc.	METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
EP3692053A1 (de)	2017-10-03	2020-08-12	Bristol-Myers Squibb Company	Immunmodulatoren
IL315737A (en)	2017-10-13	2024-11-01	Harpoon Therapeutics Inc	B-cell maturation antigen-binding proteins
SI3694529T1 (sl)	2017-10-13	2024-10-30	Harpoon Therapeutics, Inc.	Trispecifične beljakovine in načini uporabe
WO2019079362A1 (en)	2017-10-16	2019-04-25	Massachusetts Institute Of Technology	HOST-PATHOGENIC INTERACTION OF MYCOBACTERIUM TUBERCULOSIS
WO2019077062A1 (en)	2017-10-18	2019-04-25	Vivia Biotech, S.L.	C-CELLS ACTIVATED BY BIT
SG11202003625VA (en)	2017-11-03	2020-05-28	Aurigene Discovery Tech Ltd	Dual inhibitors of tim-3 and pd-1 pathways
EP3706798A1 (de)	2017-11-06	2020-09-16	Aurigene Discovery Technologies Limited	Gemeinsame therapien zur immunmodulation
WO2019094955A1 (en)	2017-11-13	2019-05-16	The Broad Institute, Inc.	Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
EP3710039A4 (de)	2017-11-13	2021-08-04	The Broad Institute, Inc.	Verfahren und zusammensetzungen zur behandlung von krebs durch targeting des clec2d-klrb1-wegs
AU2018371212B2 (en)	2017-11-24	2025-04-17	Assistance Publique - Hôpitaux De Paris	Methods and compositions for treating cancers
EP3717021A1 (de)	2017-11-27	2020-10-07	Mersana Therapeutics, Inc.	Pyrrolobenzodiazepin-antikörper-konjugate
EP3720881A1 (de)	2017-12-08	2020-10-14	Elstar Therapeutics, Inc.	Multispezifische moleküle und verwendungen davon
PE20201339A1 (es)	2017-12-19	2020-11-25	Univ Rockefeller	Variantes de dominio de fc de igg humana con funcion efectora mejorada
JP2021506883A (ja)	2017-12-21	2021-02-22	メルサナセラピューティクスインコーポレイテッド	ピロロベンゾジアゼピン抗体結合体
JP7284759B2 (ja)	2017-12-27	2023-05-31	ブリストル－マイヤーズスクイブカンパニー	抗ｃｄ４０抗体およびその使用
EP3731850A4 (de)	2017-12-29	2021-12-01	Oncorus, Inc.	Onkolytische virale verabreichung von therapeutischen polypeptiden
WO2019139987A1 (en)	2018-01-09	2019-07-18	Elstar Therapeutics, Inc.	Calreticulin binding constructs and engineered t cells for the treatment of diseases
JP2021510733A (ja)	2018-01-12	2021-04-30	ケーディーエーシーセラピューティクス，インコーポレーテッドＫｄａｃＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	がんの処置のための選択的ヒストンデアセチラーゼ３（ｈｄａｃ３）インヒビターと免疫治療剤との組み合わせ
JP7358361B2 (ja)	2018-01-12	2023-10-10	ブリストル－マイヤーズスクイブカンパニー	Ｔｉｍ３に対する抗体およびその使用
JP7214752B2 (ja)	2018-01-23	2023-01-30	ブリストル－マイヤーズスクイブカンパニー	免疫調節剤として有用な２，８－ジアシル－２，８－ジアザスピロ［５．５］ウンデカン化合物
WO2019169123A1 (en)	2018-03-01	2019-09-06	Bristol-Myers Squibb Company	Compounds useful as immunomodulators
CN111867679A (zh)	2018-03-06	2020-10-30	居里研究所	用于癌症联合治疗的setdb1组蛋白甲基转移酶抑制剂
CN112218658A (zh)	2018-03-12	2021-01-12	国家健康科学研究所	热量限制模拟物用于增强癌症治疗的化学免疫疗法的用途
MX2020009443A (es)	2018-03-14	2021-01-08	Aurigene Discovery Tech Ltd	Método de modulación de las vías de señalización de tigit y pd-1 mediante el uso de compuestos de 1,2,4-oxadiazol.
US12152073B2 (en)	2018-03-14	2024-11-26	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to calreticulin and uses thereof
EP3765516A2 (de)	2018-03-14	2021-01-20	Elstar Therapeutics, Inc.	Multifunktionale moleküle und verwendungen davon
CA3093407A1 (en)	2018-03-23	2019-09-26	Bristol-Myers Squibb Company	Antibodies against mica and/or micb and uses thereof
KR102824112B1 (ko)	2018-03-28	2025-06-24	브리스톨-마이어스 스큅 컴퍼니	인터루킨-2/인터루킨-2 수용체 알파 융합 단백질 및 사용 방법
WO2019185792A1 (en)	2018-03-29	2019-10-03	Philogen S.P.A	Cancer treatment using immunoconjugates and immune check-point inhibitors
JP2021521182A (ja)	2018-04-12	2021-08-26	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	Ｃｄ７３アンタゴニストとｐｄ−１／ｐｄ−ｌ１軸アンタゴニストの組み合わせ治療
JP7516254B2 (ja)	2018-04-18	2024-07-16	ゼンコアインコーポレイテッド	Ｉｌ－１５／ｉｌ－１５ｒａヘテロ二量体ｆｃ融合タンパク質およびその使用
CA3097593A1 (en)	2018-04-18	2019-10-24	Xencor, Inc.	Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
US11957695B2 (en)	2018-04-26	2024-04-16	The Broad Institute, Inc.	Methods and compositions targeting glucocorticoid signaling for modulating immune responses
WO2019213660A2 (en)	2018-05-04	2019-11-07	The Broad Institute, Inc.	Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses
BR112020023704A2 (pt)	2018-05-23	2021-02-17	Celgene Corporation	compostos antiproliferativos e anticorpo bispecífico contra bcma e cd3 para uso combinado
SG11202011568XA (en)	2018-05-23	2020-12-30	Celgene Corp	Treating multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-4-yl)oxy)methyl)benzyl) piperazin-1-yl)-3-fluorobenzonitrile
WO2019232319A1 (en)	2018-05-31	2019-12-05	Peloton Therapeutics, Inc.	Compositions and methods for inhibiting cd73
US20210371932A1 (en)	2018-06-01	2021-12-02	Massachusetts Institute Of Technology	Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
WO2019232528A1 (en)	2018-06-01	2019-12-05	Xencor, Inc.	Dosing of a bispecific antibody that bind cd123 and cd3
WO2020010250A2 (en)	2018-07-03	2020-01-09	Elstar Therapeutics, Inc.	Anti-tcr antibody molecules and uses thereof
CN112703011A (zh)	2018-08-06	2021-04-23	国家医疗保健研究所	用于治疗癌症的方法和组合物
EP3617230A1 (de)	2018-09-03	2020-03-04	BioInvent International AB	Neuartige antikörper und nukleotidsequenzen und verwendungen davon
WO2020048942A1 (en)	2018-09-04	2020-03-12	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for enhancing cytotoxic t lymphocyte-dependent immune responses
US11359024B2 (en)	2018-09-07	2022-06-14	Pfizer Inc.	Anti-AVB8 antibodies and compositions and uses thereof
WO2020058372A1 (en)	2018-09-19	2020-03-26	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
US12195544B2 (en)	2018-09-21	2025-01-14	Harpoon Therapeutics, Inc.	EGFR binding proteins and methods of use
EP3856771A4 (de)	2018-09-25	2022-06-29	Harpoon Therapeutics, Inc.	Dll3-bindende proteine und verfahren zur verwendung
CN113164777B (zh)	2018-09-27	2024-12-13	马伦戈治疗公司	Csf1r/ccr2多特异性抗体
WO2020070053A1 (en)	2018-10-01	2020-04-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of inhibitors of stress granule formation for targeting the regulation of immune responses
SG11202103192RA (en)	2018-10-03	2021-04-29	Xencor Inc	Il-12 heterodimeric fc-fusion proteins
US20220411783A1 (en)	2018-10-12	2022-12-29	The Broad Institute, Inc.	Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues
CR20210239A (es)	2018-10-12	2021-12-15	Xencor Inc	Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas
WO2020081730A2 (en)	2018-10-16	2020-04-23	Massachusetts Institute Of Technology	Methods and compositions for modulating microenvironment
US20210340240A1 (en)	2018-10-18	2021-11-04	INSERM (Institut National de la Santé et de la Recherche Médicale	Combination of a big-h3 antagonist and an immune checkpoint inhibitor for the treatment of solid tumor
MX2021004906A (es)	2018-10-29	2021-09-10	Mersana Therapeutics Inc	Conjugados de anticuerpo modificado con cisteína-fármaco con enlazadores que contienen péptidos.
US12402610B2 (en)	2018-11-09	2025-09-02	The Broad Institute, Inc.	Methods and compositions for modulating innate lymphoid cell pathogenic effectors
US12165743B2 (en)	2018-11-09	2024-12-10	The Broad Institute, Inc.	Compressed sensing for screening and tissue imaging
WO2020097495A1 (en)	2018-11-09	2020-05-14	Pierian Biosciences, LLC	Methods and compositions for determining the composition of a tumor microenvironment
EP3886759A1 (de)	2018-11-26	2021-10-06	Massachusetts Institute of Technology	Zusammensetzungen und verfahren für immuntoleranz
ES2971964T3 (es)	2018-11-28	2024-06-10	Inst Nat Sante Rech Med	Métodos y kit para someter a ensayo el potencial lítico de células efectoras inmunitarias
US12257340B2 (en)	2018-12-03	2025-03-25	Agensys, Inc.	Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof
WO2020115262A1 (en)	2018-12-07	2020-06-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
AU2019396360A1 (en)	2018-12-11	2021-05-27	Theravance Biopharma R&D Ip, Llc	Naphthyridine and quinoline derivatives useful as ALK5 inhibitors
EP3897624A1 (de)	2018-12-17	2021-10-27	Institut National de la Santé et de la Recherche Médicale (INSERM)	Verwendung von sulconazol als furininhibitor
CN113438961A (zh)	2018-12-20	2021-09-24	Xencor股份有限公司	含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白
MX2021007639A (es)	2018-12-27	2021-08-11	Amgen Inc	Formulaciones de virus liofilizadas.
CN113453712A (zh)	2018-12-28	2021-09-28	特兰斯吉恩股份有限公司	M2缺陷型痘病毒
WO2020141199A1 (en)	2019-01-03	2020-07-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
US11739156B2 (en)	2019-01-06	2023-08-29	The Broad Institute, Inc. Massachusetts Institute of Technology	Methods and compositions for overcoming immunosuppression
ES3059967T3 (en)	2019-01-09	2026-03-24	Celgene Corp	Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same
CA3125753A1 (en)	2019-01-09	2020-07-16	Celgene Corporation	Antiproliferative compounds and second active agents for use in treating multiple myeloma
SG11202107438WA (en)	2019-01-09	2021-08-30	Celgene Corp	Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same
KR20210121077A (ko)	2019-01-15	2021-10-07	인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)	돌연변이된 인터루킨-34 (il-34) 폴리펩티드 및 요법에서의 이의 용도
WO2020169472A2 (en)	2019-02-18	2020-08-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of inducing phenotypic changes in macrophages
US20230053540A1 (en)	2019-02-19	2023-02-23	Massachusetts Institute Of Technology	Treatment of liver injury
AU2020226893B2 (en)	2019-02-21	2025-02-27	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to T cell related cancer cells and uses thereof
GB2597851B (en)	2019-02-21	2024-05-29	Marengo Therapeutics Inc	Antibody molecules that bind to NKP30 and uses thereof
AU2020232264B2 (en)	2019-03-05	2026-02-19	Amgen Inc.	Use of oncolytic viruses for the treatment of cancer
WO2020186101A1 (en)	2019-03-12	2020-09-17	The Broad Institute, Inc.	Detection means, compositions and methods for modulating synovial sarcoma cells
EP3937969A1 (de)	2019-03-14	2022-01-19	The Broad Institute, Inc.	Zusammensetzungen und verfahren zur modulation der cgrp-signalisierung zur regulierung der angeborenen lymphoiden darmzellen
WO2020183011A1 (en)	2019-03-14	2020-09-17	Institut Curie	Htr1d inhibitors and uses thereof in the treatment of cancer
US20220152148A1 (en)	2019-03-18	2022-05-19	The Broad Institute, Inc.	Modulation of type 2 immunity by targeting clec-2 signaling
EP3942023A1 (de)	2019-03-18	2022-01-26	The Broad Institute, Inc.	Zusammensetzungen und verfahren zur modulation metabolischer regulatoren der t-zell-pathogenität
WO2020198066A1 (en)	2019-03-22	2020-10-01	Duke University	Compositions and methods for enhancing cancer immune checkpoint therapy
TW202102543A (zh)	2019-03-29	2021-01-16	美商安進公司	溶瘤病毒在癌症新輔助療法中之用途
CA3134439A1 (en)	2019-03-29	2020-10-08	Institut Curie	Interleukin-2 variants with modified biological activity
WO2020206169A1 (en)	2019-04-02	2020-10-08	Kupper Thomas S	Methods for identifying progression of a primary melanoma
US20220177978A1 (en)	2019-04-02	2022-06-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of predicting and preventing cancer in patients having premalignant lesions
US20220160692A1 (en)	2019-04-09	2022-05-26	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of sk2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer
EP3956446A1 (de)	2019-04-17	2022-02-23	INSERM (Institut National de la Santé et de la Recherche Médicale)	Verfahren und zusammensetzungen zur behandlung von durch nlrp3-inflammasom vermittelten il-1-beta-abhängigen erkrankungen
US12404331B2 (en)	2019-04-19	2025-09-02	Tcrcure Biopharma Corp.	Anti-PD-1 antibodies and uses thereof
AU2020278465B2 (en)	2019-05-20	2026-04-23	Dana-Farber Cancer Institute, Inc.	Boronic ester prodrugs and uses thereof
WO2020243371A1 (en)	2019-05-28	2020-12-03	Massachusetts Institute Of Technology	Methods and compositions for modulating immune responses
US20220243178A1 (en)	2019-05-31	2022-08-04	The Broad Institute, Inc.	Methods for treating metabolic disorders by targeting adcy5
US11246906B2 (en)	2019-06-11	2022-02-15	Alkermes Pharma Ireland Limited	Compositions and methods for subcutaneous administration of cancer immunotherapy
JP2022539248A (ja)	2019-07-02	2022-09-07	フレッドハッチンソンキャンサーリサーチセンター	組換えａｄ３５ベクター及び関連遺伝子治療改善
WO2021024020A1 (en)	2019-08-06	2021-02-11	Astellas Pharma Inc.	Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
JP7765379B2 (ja)	2019-08-12	2025-11-06	ピュリノミアバイオテック，インコーポレイテッド	Ｃｄ３９発現細胞のａｄｃｃ標的化を介してｔ細胞媒介性免疫応答を促進及び増強するための方法及び組成物
WO2021030627A1 (en)	2019-08-13	2021-02-18	The General Hospital Corporation	Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US12421557B2 (en)	2019-08-16	2025-09-23	The Broad Institute, Inc.	Methods for predicting outcomes and treating colorectal cancer using a cell atlas
KR20220100858A (ko)	2019-09-17	2022-07-18	비알 - 알&디 인베스트먼츠, 에스.에이.	치환된 이미다졸 카르복사미드, 및 질병의 치료에서의 이의 용도
EP4031540A1 (de)	2019-09-17	2022-07-27	Bial-R&D Investments, S.A.	Substituierte, gesättigte und ungesättigte n-heterozyklische carboxamide und verwandte verbindungen zur verwendung bei der behandlung von medizinischen beschwerden
KR20220100859A (ko)	2019-09-17	2022-07-18	비알 - 알&디 인베스트먼츠, 에스.에이.	산성 세라미다아제 저해제로서의 치환된 n-헤테로시클릭 카르복사미드, 및 약제로서의 이의 용도
EP4034253B1 (de)	2019-09-23	2026-01-21	The Regents Of The University Of Michigan	Zusammensetzungen zur erhöhung der wirksamkeit von immuntherapien und impfstoffen
EP3800201A1 (de)	2019-10-01	2021-04-07	INSERM (Institut National de la Santé et de la Recherche Médicale)	Cd28h-stimulierung verbessert nk-zellen-abtötungsaktivitäten
US12195725B2 (en)	2019-10-03	2025-01-14	Dana-Farber Cancer Institute, Inc.	Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
WO2021067863A2 (en)	2019-10-03	2021-04-08	Xencor, Inc.	Targeted il-12 heterodimeric fc-fusion proteins
US11981922B2 (en)	2019-10-03	2024-05-14	Dana-Farber Cancer Institute, Inc.	Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
CN114761085A (zh)	2019-10-04	2022-07-15	百时美施贵宝公司	可用作免疫调节剂的化合物
EP4037710A1 (de)	2019-10-04	2022-08-10	Institut National de la Santé et de la Recherche Médicale (INSERM)	Verfahren und pharmazeutische zusammensetzung zur behandlung von eierstockkrebs, brustkrebs oder bauchspeicheldrüsenkrebs
US11793787B2 (en)	2019-10-07	2023-10-24	The Broad Institute, Inc.	Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
TW202128757A (zh)	2019-10-11	2021-08-01	美商建南德克公司	具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
WO2021078910A1 (en)	2019-10-22	2021-04-29	Institut Curie	Immunotherapy targeting tumor neoantigenic peptides
EP4051321A4 (de)	2019-10-30	2023-11-22	Duke University	Immuntherapie mit kombinationstherapie mit einem immuntoxin
JP2022554346A (ja)	2019-11-05	2022-12-28	セルジーンコーポレーション	２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドとの併用療法
EP3824954A1 (de)	2019-11-22	2021-05-26	Centre National de la Recherche Scientifique	Vorrichtung, einrichtung und verfahren zur ministrahl-strahlentherapie
IL293084A (en)	2019-11-22	2022-07-01	Theravance Biopharma R& D Ip Llc	Substituted 1,5-naphthyridines or quinolines as alk5 inhibitors
US11865168B2 (en)	2019-12-30	2024-01-09	Massachusetts Institute Of Technology	Compositions and methods for treating bacterial infections
WO2021138407A2 (en)	2020-01-03	2021-07-08	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to cd33 and uses thereof
AU2020416273A1 (en)	2020-01-03	2022-07-28	Marengo Therapeutics, Inc.	Anti-TCR antibody molecules and uses thereof
IL272194A (en)	2020-01-22	2021-07-29	Yeda Res & Dev	Multispecific antibodies for use in treating diseases
US12165747B2 (en)	2020-01-23	2024-12-10	The Broad Institute, Inc.	Molecular spatial mapping of metastatic tumor microenvironment
TW202146452A (zh)	2020-02-28	2021-12-16	瑞士商諾華公司	結合ｃｄ１２３和ｃｄ３之雙特異性抗體的給藥
WO2021183318A2 (en)	2020-03-09	2021-09-16	President And Fellows Of Harvard College	Methods and compositions relating to improved combination therapies
EP4118118A1 (de)	2020-03-09	2023-01-18	Bristol-Myers Squibb Company	Antikörper gegen cd40 mit verbesserter agonistenaktivität
EP4126824A1 (de)	2020-03-31	2023-02-08	Theravance Biopharma R&D IP, LLC	Substituierte pyrimidine und verfahren zur verwendung
WO2021216488A1 (en)	2020-04-21	2021-10-28	Regeneron Pharmaceuticals, Inc.	Il-2 variants with reduced binding to il-2 receptor alpha and uses thereof
EP4139289A1 (de)	2020-04-21	2023-03-01	University of Rochester	Inhibitoren des humanen epididymusproteins 4
JP2023524639A (ja)	2020-04-22	2023-06-13	アイオバンスバイオセラピューティクス，インコーポレイテッド	患者特異的免疫療法用細胞の製造調整システム及び調整方法
WO2021224186A1 (en)	2020-05-04	2021-11-11	Institut Curie	New pyridine derivatives as radiosensitizers
WO2021231732A1 (en)	2020-05-15	2021-11-18	Bristol-Myers Squibb Company	Antibodies to garp
US12594302B2 (en)	2020-05-20	2026-04-07	Institut Curie	Single domain antibodies and their use in cancer therapies
CA3180060A1 (en)	2020-05-29	2021-12-02	Zongmin ZHAO	Living cells engineered with polyphenol-functionalized biologically active nanocomplexes
CA3169518A1 (en)	2020-06-03	2021-12-09	Mv Biotherapeutics Sa	Combination of an atp-hydrolyzing enzyme and an immune checkpoint modulator and uses thereof
JP2023530275A (ja)	2020-06-10	2023-07-14	セラヴァンスバイオファーマアール＆ディーアイピー，エルエルシー	Ａｌｋ５阻害剤として有用なナフチリジン誘導体
WO2021260675A1 (en)	2020-06-24	2021-12-30	Yeda Research And Development Co. Ltd.	Agents for sensitizing solid tumors to treatment
EP4171550A1 (de)	2020-06-25	2023-05-03	Celgene Corporation	Verfahren zur behandlung von krebs mit kombinationstherapien
WO2022002874A1 (en)	2020-06-30	2022-01-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery
EP4172621A1 (de)	2020-06-30	2023-05-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Verfahren zur vorhersage des risikos des wiederauftretens und/oder tods von patienten mit solidem krebs nach präoperativen adjuvanten therapien
WO2022003156A1 (en)	2020-07-02	2022-01-06	Oncurious Nv	Ccr8 non-blocking binders
CA3182579A1 (en)	2020-07-07	2022-01-13	Ugur Sahin	Therapeutic rna for hpv-positive cancer
SI4178548T1 (sl)	2020-07-07	2024-10-30	Celgene Corporation	Farmacevtski sestavki, ki obsegajo (S)-4-(4-(4-(((2-(2,6-dioksopiperidin-3-il)-1-oksoizoindolin-4-il)oksi) metil)benzil)piperazin-1-il)-3-fluorobenzonitril, in postopki uporabe le-teh
KR20230152783A (ko)	2020-07-07	2023-11-03	칸큐어 엘엘씨	Mic 항체 및 결합제 및 이의 사용 방법
US20230295146A1 (en)	2020-07-24	2023-09-21	The University Of Rochester	Inhibitors of interleukin-1 receptor-associated kinases 1 and 4
AU2021321586A1 (en)	2020-08-07	2023-03-16	Dana-Farber Cancer Institute, Inc.	Therapeutic targeting of phosphate dysregulation in cancer via the XPR1:KIDINS220 protein complex
GB2616354A (en)	2020-08-26	2023-09-06	Marengo Therapeutics Inc	Methods of detecting TRBC1 or TRBC2
EP4225330A1 (de)	2020-10-06	2023-08-16	Iovance Biotherapeutics, Inc.	Behandlung von nsclc-patienten mit tumorinfiltrierenden lymphozytentherapien
EP4229090A1 (de)	2020-10-16	2023-08-23	Université d'Aix-Marseille	Anti-gpc4-einzeldomänenantikörper
CA3196243A1 (en)	2020-10-20	2022-04-28	Angela Marinetti	Metallic trans-(n-heterocyclic carbene)-amine-platinum complexes and uses thereof for treating cancer
US20240101666A1 (en)	2020-10-23	2024-03-28	Bristol-Myers Squibb Company	Lag-3 antagonist therapy for lung cancer
JP2023548538A (ja)	2020-11-08	2023-11-17	シージェンインコーポレイテッド	併用療法
EP4247352A1 (de)	2020-11-18	2023-09-27	Institut Curie	Dimere von biguanidinen und ihre therapeutischen verwendungen
WO2022130206A1 (en)	2020-12-16	2022-06-23	Pfizer Inc.	TGFβr1 INHIBITOR COMBINATION THERAPIES
TW202245808A (zh)	2020-12-21	2022-12-01	德商拜恩迪克公司	用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en)	2020-12-21	2022-06-30	BioNTech SE	Therapeutic rna for treating cancer
WO2022135666A1 (en)	2020-12-21	2022-06-30	BioNTech SE	Treatment schedule for cytokine proteins
US20240052044A1 (en)	2020-12-24	2024-02-15	Vib Vzw	Non-blocking human ccr8 binders
EP4267617A1 (de)	2020-12-24	2023-11-01	Vib Vzw	Menschliche ccr8-bindemittel
EP4267621A1 (de)	2020-12-24	2023-11-01	Vib Vzw	Kreuzreaktive menschliche ccr8-bindemittel aus der maus
WO2022152862A1 (en)	2021-01-14	2022-07-21	Institut Curie	Her2 single domain antibodies variants and cars thereof
WO2022189618A1 (en)	2021-03-12	2022-09-15	Institut Curie	Nitrogen-containing heterocycles as radiosensitizers
WO2022204564A2 (en)	2021-03-25	2022-09-29	Iovance Biotherapeutics, Inc.	Methods and compositions for t-cell coculture potency assays and use with cell therapy products
EP4314068A1 (de)	2021-04-02	2024-02-07	The Regents Of The University Of California	Antikörper gegen gespaltenes cdcp1 und verwendungen davon
JP2024515591A (ja)	2021-04-08	2024-04-10	マレンゴ・セラピューティクス，インコーポレーテッド	Ｔｃｒに結合する多機能性分子およびその使用
EP4319820A1 (de)	2021-04-10	2024-02-14	Profoundbio Us Co.	Folr1-bindende wirkstoffe, konjugate davon und verfahren zur verwendung davon
JP7742892B2 (ja)	2021-04-23	2025-09-22	ジェンマブエー／エス	抗ｃｄ７０抗体、そのコンジュゲートおよびこれを使用する方法
CN117255789A (zh)	2021-05-05	2023-12-19	百时美施贵宝公司	可用作免疫调节剂的含内酯和内酰胺的化合物
US20240269282A1 (en)	2021-05-10	2024-08-15	Institut Curie	Methods for the Treatment of Cancer, Inflammatory Diseases and Autoimmune Diseases
WO2022251359A1 (en)	2021-05-26	2022-12-01	Theravance Biopharma R&D Ip, Llc	Bicyclic inhibitors of alk5 and methods of use
AU2022288058A1 (en)	2021-06-07	2023-11-16	Agonox, Inc.	Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
EP4352077A1 (de)	2021-06-09	2024-04-17	Bristol-Myers Squibb Company	Zyklische peptidimmunmodulatoren
EP4367269A1 (de)	2021-07-05	2024-05-15	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Gensignaturen zur vorhersage der überlebenszeit bei patienten mit nierenzellkarzinom
WO2023283523A1 (en)	2021-07-06	2023-01-12	Bristol-Myers Squibb Company	2,3-dihydrobenzo[b][l,4]dioxin-6-yl containing compounds useful as immunomodulators
CA3225254A1 (en)	2021-07-13	2023-01-19	BioNTech SE	Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
WO2023011879A1 (en)	2021-08-05	2023-02-09	Institut Curie	Scanning dynamic device for minibeams production
WO2023028501A1 (en)	2021-08-23	2023-03-02	Immunitas Therapeutics, Inc.	Anti-cd161 antibodies and uses thereof
WO2023041744A1 (en)	2021-09-17	2023-03-23	Institut Curie	Bet inhibitors for treating pab1 deficient cancer
TW202333802A (zh)	2021-10-11	2023-09-01	德商拜恩迪克公司	用於肺癌之治療性rna(二)
US20250019708A1 (en)	2021-11-19	2025-01-16	Institut Curie	Methods for the treatment of hrd cancer and brca-associated cancer
CA3238167A1 (en)	2021-11-19	2023-05-25	Maria Leia Smith	Gpc3 binding agents, conjugates thereof and methods of using the same
WO2023099763A1 (en)	2021-12-03	2023-06-08	Institut Curie	Sirt6 inhibitors for use in treating resistant hrd cancer
CN118742568A (zh)	2021-12-23	2024-10-01	布罗德研究所股份有限公司	并行抗体工程化组合物和方法
WO2023154799A1 (en)	2022-02-14	2023-08-17	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Combination immunotherapy for treating cancer
JP2025508076A (ja)	2022-03-08	2025-03-21	アレンティス・セラピューティクス・アクチェンゲゼルシャフト	Ｔ細胞の利用能を向上させるための抗クローディン－１抗体の使用
CA3254182A1 (en)	2022-03-24	2023-09-28	Universite Paris Cite	Immunotherapy targeting neoantigenic peptides derived from a tumor-specific transposable element in a glioblastoma
WO2023187024A1 (en)	2022-03-31	2023-10-05	Institut Curie	Modified rela protein for inducing interferon expression and engineered immune cells with improved interferon expression
JP2025511383A (ja)	2022-04-07	2025-04-15	アンスティテュキュリィ	キメラ抗原受容体で改変された骨髄系細胞及び抗がん治療のためのその使用
WO2023194607A1 (en)	2022-04-07	2023-10-12	Institut Curie	Myeloid cells modified by chimeric antigen receptor with cd40 and uses thereof for anti-cancer therapy
WO2023201369A1 (en)	2022-04-15	2023-10-19	Iovance Biotherapeutics, Inc.	Til expansion processes using specific cytokine combinations and/or akti treatment
WO2023213764A1 (en)	2022-05-02	2023-11-09	Transgene	Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en)	2022-05-02	2023-11-09	Transgene	Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
AU2023300419A1 (en)	2022-07-01	2025-01-02	Transgene	Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
AU2023307223A1 (en)	2022-07-14	2025-02-20	The Broad Institute, Inc.	Aav capsids that enable cns-wide gene delivery through interactions with the transferrin receptor
WO2024052356A1 (en)	2022-09-06	2024-03-14	Institut National de la Santé et de la Recherche Médicale	Inhibitors of the ceramide metabolic pathway for overcoming immunotherapy resistance in cancer
EP4593868A1 (de)	2022-09-26	2025-08-06	Institut Curie	Myeloidzellen zur expression von il-2 und verwendungen davon zur schnellen antikrebstherapie
EP4604939A1 (de)	2022-10-20	2025-08-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Kombinationstherapie zur behandlung von krebs
WO2024086827A2 (en)	2022-10-20	2024-04-25	Repertoire Immune Medicines, Inc.	Cd8 t cell targeted il2
WO2024089417A1 (en)	2022-10-24	2024-05-02	Memorial Sloan-Kettering Cancer Center	Tumour stratification for responsiveness to an immune checkpoint inhibitor
EP4608390A1 (de)	2022-10-24	2025-09-03	Cancer Research Technology Limited	Tumorsensibilisierung gegen checkpoint-inhibitoren mit redoxstatus-modifikator
KR20250122544A (ko)	2022-11-21	2025-08-13	이오반스 바이오테라퓨틱스, 인크.	종양 침윤 림프구의 확장을 위한 2차원 공정 및 이를 통한 요법
EP4634224A1 (de)	2022-12-14	2025-10-22	Astellas Pharma Europe Bv	Kombinationstherapie mit bispezifischen bindemitteln, die an cldn18.2 und cd3 binden, und immuncheckpoint-inhibitoren
WO2024163477A1 (en)	2023-01-31	2024-08-08	University Of Rochester	Immune checkpoint blockade therapy for treating staphylococcus aureus infections
WO2024192141A1 (en)	2023-03-13	2024-09-19	Dana-Farber Cancer Institute, Inc.	Treatment of cancers having a drug-resistant mesenchymal cell state
WO2024194673A1 (en)	2023-03-21	2024-09-26	Institut Curie	Methods for the treatment of dedifferentiated liposarcoma
WO2024194401A1 (en)	2023-03-21	2024-09-26	Institut Curie	Vps4b inhibitor for use in methods for the treatment of hrd cancer
WO2024194402A1 (en)	2023-03-21	2024-09-26	Institut Curie	Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer
WO2024213782A1 (en)	2023-04-13	2024-10-17	Institut Curie	Methods for the treatment of t-cell acute lymphoblastic leukemia
WO2024213767A1 (en)	2023-04-14	2024-10-17	Institut National de la Santé et de la Recherche Médicale	Engraftment of mesenchymal stromal cells engineered to stimulate immune infiltration in tumors
WO2024261302A1 (en)	2023-06-22	2024-12-26	Institut National de la Santé et de la Recherche Médicale	Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
WO2025003193A1 (en)	2023-06-26	2025-01-02	Institut National de la Santé et de la Recherche Médicale	Sertraline and indatraline for disrupting intracellular cholesterol trafficking and subsequently inducing lysosomal damage and anti-tumor immunity
WO2025012417A1 (en)	2023-07-13	2025-01-16	Institut National de la Santé et de la Recherche Médicale	Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
TW202521562A (zh)	2023-08-11	2025-06-01	美商默沙東有限責任公司	單價介白素-12(IL-12) 異二聚體Fc蛋白
WO2025068393A1 (en)	2023-09-27	2025-04-03	Institut Curie	Methods for the treatment of fibrotic related diseases
AR134560A1 (es)	2023-12-08	2026-01-28	Astellas Pharma Inc	Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2
WO2025120866A1 (en)	2023-12-08	2025-06-12	Astellas Pharma Inc.	Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120867A1 (en)	2023-12-08	2025-06-12	Astellas Pharma Inc.	Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2026033885A1 (en)	2024-08-08	2026-02-12	Astellas Pharma Inc.	Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
EP4574165A1 (de)	2023-12-21	2025-06-25	Egle Therapeutics	Immunozytokine zur krebsbehandlung
WO2025133175A1 (en)	2023-12-21	2025-06-26	Egle Therapeutics	Immunocytokine for cancer treatment
WO2025155923A1 (en)	2024-01-17	2025-07-24	The Broad Institute, Inc.	Aav capsid modifications that enable improved cns-wide gene delivery through interactions with the transferrin receptor
WO2025158077A1 (en)	2024-01-26	2025-07-31	Institut Curie	Lipid degraders to trigger ferroptosis in cancer
TW202545567A (zh)	2024-01-30	2025-12-01	美商思進公司	抗ｐｄ－ｌ１抗體和抗體－藥物共軛體及彼等在治療癌症的用途
WO2025202222A1 (en)	2024-03-25	2025-10-02	Institut National de la Santé et de la Recherche Médicale	Therapeutic use of sting and tlrs agonists to induce p16 expression in immune cells
WO2025202213A1 (en)	2024-03-26	2025-10-02	Institut National de la Santé et de la Recherche Médicale	Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells
WO2025202450A1 (en)	2024-03-28	2025-10-02	Institut Curie	Myeloid cells modified by cytokine chimeric receptor and uses thereof
EP4624494A1 (de)	2024-03-29	2025-10-01	Institut Curie	Her2-einzeldomänenantikörper und verwendungen davon
WO2025210175A1 (en)	2024-04-04	2025-10-09	Centre National De La Recherche Scientifique	Mutant csf-1r extracellular domain fusion molecules and therapeutic uses thereof
WO2025210252A1 (en)	2024-04-05	2025-10-09	Institut Curie	Modulators of fam118b protein for use in therapy
WO2025217163A2 (en)	2024-04-08	2025-10-16	The Broad Institute, Inc.	Novel aav capsids binding to human cd59
WO2025217174A1 (en)	2024-04-08	2025-10-16	The Broad Institute, Inc.	Aav capsid modifications that enable improved cns-wide gene delivery through interactions with carbonic anhydrase iv
WO2025217094A1 (en)	2024-04-08	2025-10-16	University Of Rochester	Interleukin receptor-associated kinase (irak) protac degraders and medical use thereof
WO2025217096A1 (en)	2024-04-08	2025-10-16	University Of Rochester	Inhibitors of leucine-rich repeat kinase 2 (lrrk2) and medical uses thereof
WO2025219595A1 (en)	2024-04-19	2025-10-23	Biper Therapeutics	Method for combination treatments using alkynylbenzenesulphonamides for cancer therapy
WO2025232879A1 (en)	2024-05-10	2025-11-13	Cytocares (Shanghai) Inc.	Anti-lilrb2 monospecific and bispecific antibody constructs and uses thereof
GB202408360D0 (en)	2024-06-11	2024-07-24	Cancer Research Tech Ltd	Tumour sensitisation
WO2026012976A1 (en)	2024-07-08	2026-01-15	Institut National de la Santé et de la Recherche Médicale	Use of inhibitor of gasdermind for treatment of rac2 monogenic disorders
WO2026037841A1 (en)	2024-08-12	2026-02-19	ONA Therapeutics S.L.	Anti-fgfr4 molecules and uses thereof
US20260048137A1 (en)	2024-08-16	2026-02-19	Ardeagen Corporation	Anti-mesothelin antibody conjugates and methods of use thereof
GB202412414D0 (en)	2024-08-23	2024-10-09	Univ Bradford	Methods for treating cancer
WO2026050572A2 (en)	2024-08-29	2026-03-05	Marengo Therapeutics, Inc.	Multifunctional molecules binding to tcr and uses thereof
EP4707295A1 (de)	2024-09-05	2026-03-11	Egle Therapeutics	Interleukin-2-varianten mit modifizierter biologischer aktivität
EP4707296A1 (de)	2024-09-05	2026-03-11	Egle Therapeutics	Interleukin-2-varianten mit modifizierter biologischer aktivität
WO2026052851A2 (en)	2024-09-09	2026-03-12	Institut National de la Santé et de la Recherche Médicale	Inhibitor of ciliogenesis for use in a method of preventing therapeutic resistance in cancer
WO2026093526A1 (en)	2024-10-31	2026-05-07	Institut National de la Santé et de la Recherche Médicale	Methods of predicting cancer in patients having premalignant lesions
WO2026093520A1 (en)	2024-10-31	2026-05-07	Institut Curie	Short-csf1-associated extracellular vesicles and uses thereof
WO2026093435A1 (en)	2024-10-31	2026-05-07	Institut National de la Santé et de la Recherche Médicale	Use of jak inhibitors for enhancing the potency of immunotherapy in the treament of cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US556763A (en) *		1896-03-24		Telephone-switch
EP0606217B2 (de) *	1991-06-27	2008-12-03	Bristol-Myers Squibb Company	CTL4A Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendungen
US6090914A (en) *	1991-06-27	2000-07-18	Bristol-Myers Squibb Company	CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5770197A (en) *	1991-06-27	1998-06-23	Bristol-Myers Squibb Company	Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
US5556763A (en) *	1992-04-06	1996-09-17	United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Evaluation and treatment of patients with progressive immunosuppression
JPH08506247A (ja) *	1993-07-09	1996-07-09	アムジェンボールダーインコーポレイテッド	組換えｃｔｌａ４ポリペプチドおよびその製造方法
WO1995003408A1 (en) *	1993-07-26	1995-02-02	Dana-Farber Cancer Institute	B7-2: ctl a4/cd 28 counter receptor
AU7526894A (en) *	1993-08-16	1995-03-14	Arch Development Corporation	B7-2: ctla4/cd28 counter receptor
US6218510B1 (en) *	1994-03-02	2001-04-17	Brigham & Woman's Hospital	B7-1 and B7-2 polypeptides
ES2153895T3 (es) *	1994-03-08	2001-03-16	Dana Farber Cancer Inst Inc	Metodos para modular la insensibilidad de celulas t.
US6719972B1 (en) *	1994-06-03	2004-04-13	Repligen Corporation	Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
EP0784482A2 (de) *	1994-06-07	1997-07-23	The Regents Of The University Of Minnesota	Methode zur inhibition der antigen spezifischen t-zellen immunantwort
AU4158396A (en) *	1994-11-10	1996-06-06	Dana-Farber Cancer Institute	Methods for inhibiting graft versus host disease in bone marrow transplantation

1996
- 1996-05-08 US US08/646,605 patent/US5811097A/en not_active Expired - Lifetime
- 1996-12-04 CA CA2239448A patent/CA2239448C/en not_active Expired - Lifetime
- 1996-12-04 JP JP52142597A patent/JP4477701B2/ja not_active Expired - Lifetime
- 1996-12-04 EP EP08020208.8A patent/EP2106800B1/de not_active Expired - Lifetime
- 1996-12-04 DK DK10180032.4T patent/DK2332561T3/en active
- 1996-12-04 AU AU11473/97A patent/AU730500B2/en not_active Expired
- 1996-12-04 CA CA2770851A patent/CA2770851C/en not_active Expired - Lifetime
- 1996-12-04 PT PT96942901T patent/PT865293E/pt unknown
- 1996-12-04 DE DE69637762T patent/DE69637762D1/de not_active Expired - Fee Related
- 1996-12-04 ES ES10180032.4T patent/ES2579277T3/es not_active Expired - Lifetime
- 1996-12-04 EP EP96942901A patent/EP0865293B1/de not_active Revoked
- 1996-12-04 EP EP10180032.4A patent/EP2332561B1/de not_active Expired - Lifetime
- 1996-12-04 WO PCT/US1996/019375 patent/WO1997020574A1/en not_active Ceased
- 1996-12-04 PT PT101800324T patent/PT2332561E/pt unknown
- 1996-12-04 DK DK96942901T patent/DK0865293T3/da active
- 1996-12-04 ES ES96942901T patent/ES2318853T3/es not_active Expired - Lifetime
- 1996-12-04 AT AT96942901T patent/ATE415172T1/de active
2008
- 2008-11-13 JP JP2008291542A patent/JP2009114191A/ja not_active Withdrawn
2012
- 2012-01-05 DE DE201212000002 patent/DE122012000002I1/de active Pending
- 2012-01-09 LU LU91927C patent/LU91927I2/fr unknown

Also Published As

Publication number	Publication date
DE122012000002I1 (de)	2012-06-14
JP2000502331A (ja)	2000-02-29
WO1997020574A1 (en)	1997-06-12
ES2579277T3 (es)	2016-08-09
JP2009114191A (ja)	2009-05-28
LU91927I2 (fr)	2012-03-09
US5811097A (en)	1998-09-22
EP0865293A4 (de)	2002-02-06
EP2332561A1 (de)	2011-06-15
DE69637762D1 (de)	2009-01-08
PT2332561E (pt)	2016-06-14
CA2239448C (en)	2013-10-01
AU730500B2 (en)	2001-03-08
EP0865293A1 (de)	1998-09-23
PT865293E (pt)	2009-03-06
CA2770851A1 (en)	1997-06-12
EP2106800A1 (de)	2009-10-07
ES2318853T3 (es)	2009-05-01
DK2332561T3 (en)	2016-06-06
EP2106800B1 (de)	2016-12-07
EP2332561B1 (de)	2016-03-30
JP4477701B2 (ja)	2010-06-09
EP0865293B1 (de)	2008-11-26
AU1147397A (en)	1997-06-27
ATE415172T1 (de)	2008-12-15
DK0865293T3 (da)	2009-03-23
CA2239448A1 (en)	1997-06-12

Legal Events

Date	Code	Title	Description
2012-03-09	EEER	Examination request
2017-02-06	MKEX	Expiry	Effective date: 20161205

Publication	Publication Date	Title
US7229628B1 (en)	2007-06-12	Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
CA2239448C (en)	2013-10-01	Blockade of t lymphocyte down-regulation associated with ctla-4 signaling
US5855887A (en)	1999-01-05	Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
CA2352783C (en)	2012-04-10	Stimulation of t cells against self antigens using ctla-4 blocking agents
US7579001B2 (en)	2009-08-25	Antagonists of TWEAK and of TWEAK receptor and their use to treat immunological disorders
US20090123421A1 (en)	2009-05-14	Anti-lymphotoxin-beta receptor antibodies as anti-tumor agents
AU727652B2 (en)	2000-12-21	Nerve growth factor as a vaccine adjuvant
KR100470739B1 (ko)	2005-09-02	항종양제로서의림프독소-α/β복합체및항-림프독소-β수용체항체
WO1996011020A1 (en)	1996-04-18	Rheumatoid arthritis remedy containing il-6 antagonist as active ingredient
US20090269353A1 (en)	2009-10-29	Stimulation of T Cells Against Self-Antigens Using CTLA-4 Blocking Agents
JPH11505516A (ja)	1999-05-21	抗体クラススイッチを刺激する組成物及び方法
US7476385B2 (en)	2009-01-13	Methods of inhibiting IgE responses to thymus-dependent antigens with the anti-gp39 antibody MR1